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ABSTRACT 
 Obesity is characterized as a state of chronic low-grade inflammation, which 
originates in adipose tissue from adipocyte dysfunction as a consequence of adipocyte 
hypertrophy.  Although rodent models have been pivotal to understanding the etiology of 
obesity and its co-morbidities, and the roles of specific genes, distinct differences between 
rodents and humans underscore the need for alternative comparative models.  Swine are an 
attractive comparative model because of similar physiology and anatomy with humans.  
Ossabaw swine are of particular interest due to their “thrifty” genotype and predisposition to 
multiple risk factors for the metabolic syndrome. 
 Saturated fatty acids have the distinct ability to induce inflammation and insulin 
resistance via activation of toll-like receptor 4, while n-3 fatty acids generally reduce 
inflammation and restore insulin sensitivity.  Therefore, we first used Ossabaw swine to 
investigate the effects of high saturated fat and high saturated fat plus n-3 fatty acids on 
adipose tissue macrophages, inflammation, and insulin resistance.  In this study, despite 
severe obesity, Ossabaw swine did not develop systemic inflammation.  Consumption of the 
high palm oil diet did decrease serum adiponectin, and this decrease was attenuated by the 
addition of n-3 fatty acids to the diet.  Additionally, we determined that the majority of 
adipose tissue macrophages are of an anti-inflammatory phenotype.  High dietary palm oil 
did increase the percentage of inflammatory macrophages, and this increase was attenuated 
by the addition of n-3 fatty acids.  Finally, the consumption of high palm oil induced insulin 
resistance, which was attenuated by the addition of n-3 fatty acids.  Thus, in Ossabaw swine, 
morbid obesity induces insulin resistance, but insulin resistance is not linked to 
inflammation.  
xi 
 
Obesity in humans and rodents causes an increase in subcutaneous adipocyte size of 
~2 to 3 fold.  Ossabaw subcutaneous adipocyte size was increased ~4.3 fold due to the 
consumption of a diet high in fat.  Because of marked adipocyte hypertrophy coupled with 
the lack of inflammation in obese Ossabaw adipocytes, we sought to determine if Ossabaw 
adipocytes were protected against saturated fatty acid-induced inflammation.  Therefore, we 
investigated the differences between Ossabaw and Yorkshire stromal vascular cell-derived 
adipocytes with respect to differentiation and palmitate-induced inflammation and insulin 
resistance. In this study, we determined that Ossabaw adipocytes express more peroxisome 
proliferator-activated receptor , have more glycerol-3-phosphate dehydrogenase activity, 
and higher rates of clonal expansion than Yorkshire adipocytes.  These finding indicate that 
Ossabaw adipocytes differentiate to a greater extent than Yorkshire adipocytes.  Palmitate 
decreased insulin-stimulated glucose uptake in both adipocyte genotypes.  However, 
Ossabaw adipocytes had decreased basal and insulin-stimulated glucose uptake compared 
with Yorkshire adipocytes, although the fold increase was not different with insulin 
stimulation.  With respect to inflammation, palmitate induced nuclear factor  B activation 
equally in both adipocyte genotypes, but only Yorkshire adipocytes secreted interleukin 8 in 
response to palmitate. Consistent with this, there were no differences in serum or adipose 
tissue IL-8 concentrations between lean and obese Ossabaw swine.  Interleukin 8 induces 
neutrophil chemotaxis into tissues.  Neutrophil infiltration into adipose tissue may be 
important in the early stages of obesity.  These data suggest that differences in Ossabaw 
adipocytes compared with Yorkshire adipocytes may be instrumental in protecting against 
inflammation during high fat diet-induced obesity. 
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 Finally, we evaluated global gene expression in subcutaneous and visceral adipose 
tissue of restricted and ad libitum fed Ossabaw swine by using an Affymetrix microarray.  
Microarray analysis revealed no differentially expressed genes between lean and obese 
Ossabaw swine. This result coincides with no metabolic alterations induced by obesity 
relating to glucose homeostasis or serum lipids.  There were a total of 1494 genes 
differentially expressed by adipose tissue depot, of which 777 were annotated.  DAVID was 
used to identify functional categories that contained over-represented genes that were 
differentially expressed by depot.  Extracellular space was identified as a gene ontology 
cellular component category.  Two KEGG pathways were identified by DAVID.  These were 
arachidonic acid metabolism and chemokine signaling pathway. 
 Collectively, we have demonstrated that dietary factors influence the development of 
metabolic alterations in Ossabaw swine as evidenced by the induction of insulin resistance by 
high dietary palm oil, the attenuation of insulin resistance by the addition of n-3 fatty acids, 
and the lack of differentially expressed genes in the adipose tissue of obese Ossabaw swine 
when consuming a diet without added fat.  Additionally, even in the presence of insulin 
resistance, there was minimal evidence of inflammation beyond the slight increase in the 
inflammatory CD16
−
CD14+ macrophages in the adipose tissue of Ossabaw swine fed a high 
dietary palm oil.  Palmitate-induced interleukin 8 secretion by Yorkshire adipocytes, but not 
Ossabaw adipocytes, further supports that Ossabaw swine are resistant to obesity-linked 
inflammation.  The ability of Ossabaw swine to expand adipose tissue may afford protection 
against the induction of inflammation by diet-induced obesity.  Further research into the role 
of adipose expansion and protection against inflammation is warranted.
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CHAPTER 1: GENERAL INTRODUCTION 
Introduction 
In 2007-2008, it was estimated that 33.9% of the population in the United States is 
obese (BMI ≥ 30) (3), compared with 30.5% in 1999-2000 (4).  Obesity and its co-
morbidities have placed a significant economic burden on our health care system (20-21; 26).  
Obesity is linked with a cluster of co-morbidities, that when present, meet the defining 
criteria for the metabolic syndrome.  The metabolic syndrome places individuals at a greater 
risk for the development of type 2 diabetes (5; 14) and cardiovascular disease (6; 14).  
Additionally, visceral adiposity and fatty liver associated with obesity pose a greater risk for 
the development of the metabolic syndrome (9).  Because of the increase in prevalence of 
obesity, there has been increased research effort directed at understanding the etiology of the 
epidemic and identifying potential interventions. 
 Adipose tissue, once considered just an energy storage tissue, is now recognized as a 
fully functional endocrine and immune tissue. This tissue produces hormones, cytokines, and 
chemokines that modulate metabolic and immunological pathways, both centrally and in 
peripheral tissues.  These molecules are termed adipokines.  Chronic positive energy balance 
induces adipose tissue expansion via adipocyte hypertrophy and/or preadipocyte hyperplasia.  
Adipocyte hypertrophy and dysregulation leads to an altered adipokine profile that precedes 
macrophage infiltration (8).  Adipose remodeling, or turnover of these “enlarged” adipocytes 
leads to the recruitment of macrophages, which assist in the necrosis of adipocytes (23).  
Adipocyte hypertrophy and macrophage infiltration alter adipose tissue production and 
secretion of adipokines such as tumor necrosis factor (TNF) , interleukin 6 (IL-6), C-
reactive protein (CRP), monocyte chemoattractant protein 1 (MCP-1), IL-8, and adiponectin.  
2 
 
Collectively, obesity-induced dysregulation of these adipokines can induce adipose tissue 
insulin resistance, leading to ectopic lipid deposition, particularly in the liver (2), muscle 
(18), and pancreas (22).   
 Consumption of saturated fat can contribute to adipose tissue inflammation.  
Saturated fatty acids are a ligand for toll-like receptor 4 (11), the innate immune receptor for 
lipopolysaccharide, and leads to the activation of nuclear factor  B (NFB) and subsequent 
inflammation.  Conversely, n-3 fatty acids are generally considered anti-inflammatory.  
Eicospentaenoic acid and docosahexaenoic acid are the n-3 fatty acids with biological 
activity.  These n-3 fatty acids can inhibit NFB (10; 17) and activate peroxisome 
proliferator-activated receptor  (1). 
Nearly a decade after the link between obesity, inflammation, and insulin resistance 
was established (7), two laboratories independently discovered that obesity is associated with 
macrophage accumulation in adipose tissue (27-28).  Consistent with this, both body mass 
and adipocyte size are positively correlated with the number of macrophages present in 
adipose tissue (27).   
Mice have been pivotal to the determination of the role of macrophages in adipose 
tissue.  However, distinct differences between human and murine immune function, 
particularly regarding the role of CRP as an acute phase protein (24) and nitric oxide 
production in macrophages (15; 19; 25), limit mice as an immunological model for humans.  
Swine are increasingly used as a biomedical research model, in large part because of their 
similar physiology and anatomy with humans (12).  Recently, swine have been used to study 
a number of issues relating to obesity, including cardiovascular disease, steatohepatitis, and 
insulin signaling.  Ossabaw swine are of particular interest, given their “thrifty” genotype due 
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to genetic isolation (13) and ability to develop all of the risk factors associated with the 
metabolic syndrome (16).   
Despite evidence demonstrating the value of swine as a model of obesity, there has 
not been an evaluation of adipose tissue inflammation in swine under conditions of diet-
induced obesity, particularly regarding macrophage infiltration and induction of 
inflammation via saturated fatty acids, and the inhibition by n-3 fatty acids.  Consequently, 
there is a clear need to demonstrate adipose tissue inflammation and macrophage infiltration 
in Ossabaw swine, and to determine the effects of saturated and n-3 fatty acids on 
inflammation to further evaluate swine as a comparative model for human obesity.   
Objective and Specific Aims 
 The objective of this study was to determine the extent to which Ossabaw swine 
develop adipose tissue inflammation and macrophage infiltration, and its effects on insulin 
sensitivity under conditions of diet-induced obesity.  The central hypothesis was that diet-
induced obesity will cause adipose tissue inflammation concomitant with macrophage 
infiltration in Ossabaw swine.  The rationale for our work was to establish a link between 
adipose tissue inflammation and obesity-linked metabolic consequences in an alternative 
comparative model for human obesity.  Our specific aims include i) to determine the effect of 
saturated and n-3 fatty acids on insulin resistance and macrophage phenotype in Ossabaw 
swine, ii) to determine the effect of saturated fatty acids on Ossabaw and Yorkshire 
adipocytes in regards to inflammation and insulin resistance, and iii) identify specific gene 
categories and pathways in Ossabaw swine adipose tissue that are involved in adipose tissue 
expansion due to diet-induced obesity. 
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CHAPTER 2: LITERATURE REVIEW 
Obesity Prevalence 
 Obesity is an increasing trend in the United States and other developed countries.  In 
2007-2008, it was estimated that 33.9% of the population in the United States is obese (BMI 
≥ 30) and 68.3% is overweight (BMI ≥ 25) (92).  In comparison, the estimates were 30.5% 
and 64.5%, respectively, in 1999-2000 (93).  Obesity and its co-morbidities have placed a 
significant economic burden on our health care system, and costs are continuing to rise (237; 
242; 279).  In part, due to public health concern and economic cost, obesity and its co-
morbidities have become a large research focus to understand the etiology of the epidemic 
and to identify potential interventions.  However, a myriad of factors, including genotype and 
environment can contribute to the increasing prevalence of obesity.  
Common polymorphisms in the FTO (fat mass and obesity associated) gene and near 
the melanocortin 4 receptor gene have been associated with the increased risk of obesity.  
These polymorphisms are associated with increased fat mass and increased risk of obesity 
(44; 70; 99; 176).  Additionally, the presence of multiple risk alleles has an additive effect on 
the risk of obesity (44).  However, the presence of single nucleotide polymorphisms (SNP) 
cannot completely account for the increased incidence in obesity.  For example, the SNP 
rs1421085 in the FTO gene has an allelic frequency of 0.460 for the risk allele from a US 
population of European descent, but only a frequency of 0.066 for a United States population 
of African descent (HapMap).  Clearly, more than genetic susceptibility contributes to the 
increase in obesity prevalence. Thus, genetic susceptibility, in conjunction with urbanization 
and poor diets has facilitated the increase in obesity prevalence (268).   
8 
 
 Obesity is associated with a cluster of co-morbidities that, when present, is defined as 
the metabolic syndrome.  The presence of the metabolic syndrome places individuals at a 
greater risk for the development of type 2 diabetes (98; 191) and cardiovascular disease (105; 
191).  The International Diabetes Federation and the American Heart Association/National 
Heart, Lung, and Blood Institute define the metabolic syndrome as meeting three out of the 
five following criteria: waist circumference greater than 102 cm for men and 88 cm for 
women, serum triglycerides greater than 150 mg/dL, HDL cholesterol less than 40 mg/dL for 
men and 50 mg/dL for women, fasting blood glucose greater than 100 mg/dL, and 
hypertension with systolic blood pressure greater than 130 mm Hg or diastolic blood pressure 
greater than 85 mm Hg (7).  Additionally, visceral adiposity and fatty liver associated with 
obesity place individuals at a greater risk for the development of the metabolic syndrome 
(146).   
Obesity, Inflammation, and Insulin Resistance 
Adipose Tissue Expansion 
 Adipose tissue, once considered just an energy storage tissue, is now recognized as a 
fully functional endocrine and immune organ. This tissue produces a myriad of hormones, 
cytokines, and chemokines that are capable of modulating metabolic and immunological 
pathways, both centrally and in peripheral tissues.  These molecules, collectively referred to 
as adipokines, include cytokines, chemokines, adhesion molecules, angiogenic factors, and 
growth factors that regulate food intake, metabolism, vascularization, reproduction, adipose 
development, inflammation, and inflammatory cell recruitment (53; 116; 178).  Nearly all of 
the co-morbidities associated with obesity can be linked to chronic inflammation (9; 197; 
307). 
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 Chronic positive energy balance induces adipose tissue expansion via adipocyte 
hypertrophy and/or preadipocyte hyperplasia.  Evidence suggests that adipose tissue 
hypertrophy is genetically limited and varies by depot (69).  Adipocyte hypertrophy and 
dysregulation leads to an altered adipokine profile which precedes macrophage infiltration 
(131).  Death and necrosis of adipocytes, as well as pro-inflammatory adipokine secretion, is 
positively linked to adipocyte size (54; 129; 250).  Adipose remodeling, or turnover of these 
“enlarged” adipocytes, leads to the recruitment of macrophages, which assist in the necrosis 
of adipocytes (259).  Adipokine-mediated inflammation furthers the recruitment of 
macrophages and leads to increased inflammation (137; 287).  Adipocyte hypertrophy and 
macrophage infiltration alter adipose tissue production and secretion of adipokines such as 
tumor necrosis factor (TNF) , interleukin 6 (IL-6), C-reactive protein (CRP), monocyte 
chemoattractant protein 1 (MCP-1), IL-8, and adiponectin as well as others.  
Adipose tissue inflammation is a potential link between insulin resistance and the 
eventual development of type 2 diabetes mellitus.  It is estimated that 80 % of diabetics are 
considered overweight and 49 % are obese (204).  Thus, there is a strong link between 
obesity and the development of type 2 diabetes mellitus.    
Adipose tissue insulin resistance results in aberrant regulation of the balance between 
lipogenesis and lipolysis (18).  As a consequence, lipolysis is favored and circulating 
concentrations of free fatty acids are increased.  Additionally, postprandial lipid storage is 
impaired, which further contributes to dyslipidemia (189).  As a result, ectopic lipid 
deposition occurs particularly in the liver (73), muscle (220), and pancreas (246).  Ectopic 
lipid deposition in the liver and muscle is associated with insulin resistance (151; 181), 
potentially increasing hepatic glucose production and decreasing skeletal muscle glucose 
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uptake.  Furthermore, ectopic lipid deposition in the pancreas can lead to a decrease in -cell 
function (246), exacerbating insulin resistance and leading to the development of frank 
diabetes.  
However, some obese individuals do not display the metabolic phenotype often 
associated with obesity (141; 248).  These individuals are termed metabolically healthy but 
obese (MHO).  MHO individuals retain high levels of insulin sensitivity, and have a 
favorable lipid and inflammatory profile (3; 35; 140; 254).  Body composition may be a 
determining factor in the MHO phenotype.  As such, MHO individuals have less visceral (35; 
128; 140; 247; 288) and liver (254) fat compared to their metabolically abnormal 
counterparts.  Potentially, the ability to expand adipose tissue may be a fundamental 
component to the favorable metabolic profile in MHO individuals.  In ob/ob mice, the 
induction of adipose tissue expansion attenuates insulin resistance and improves systemic 
inflammation normally seen in this model, despite morbid obesity (145).  This improvement 
was accompanied by smaller adipocytes and decreased ectopic lipid deposition, suggesting 
that limits on the ability of adipose tissue to expand cause adipocyte hypertrophy and leads to 
ectopic lipid deposition that may be causal to the development of insulin resistance in obese 
individuals. 
Insulin Signaling 
  Insulin is responsible for multiple biological effects, including stimulation of glucose 
uptake, lipogenesis, protein synthesis, glycogen synthesis, gene transcription, and growth and 
differentiation.  Upon binding of insulin to the insulin receptor, the receptor undergoes auto-
phosphorylation of tyrosine residues.  Auto-phosphorylation allows the docking and tyrosine 
phosphorylation of insulin receptor substrate (IRS) proteins (i.e., IRS-1, IRS-2).   Tyrosine 
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phosphorylation of IRS allows the binding of several adaptor proteins including 
phosphatidylinositol 3-kinase (PI3K).  PI3K catalyzes the conversion of phosphatidylinositol 
4,5-bisphosphate to phosphatidylinositol 3,4,5-triphosphate, leading to the down-stream 
activation of protein kinase B (PKB, i.e., Akt) by phosphorylation of threonine 308 and 
serine 473, and eventual translocation of GLUT4 to the plasma membrane (as reviewed by 
Taha and Klip) (266). 
Tumor Necrosis Factor  
TNF is an adipokine that can act both locally and systemically (142).  In humans, 
the production of TNF is elevated in obesity (142-143; 186), but decreases with weight loss 
(63; 143). TNF has two receptors, TNFR1 and TNFR2.  TNFR1 is the major receptor in 
adipose tissue, leading to the activation of nuclear factor  B (NFB), and mitogen-activated 
protein kinases (MAPK) such as extracellular signal-regulated protein kinase (ERK), p38 
MAPK, and c-Jun N-terminal kinase (JNK) (45).  In obesity, elevated TNF concentrations 
are directly linked to insulin resistance (123) and cardiovascular disease (249).  Additionally, 
TNF up-regulates the expression other of pro-inflammatory adipokines (186; 278), and 
down-regulates the expression of anti-inflammatory adipokines, such as adiponectin (37; 
233; 278).  At the expense of inflammation and insulin resistance, increased TNF 
concentrations during obesity may be viewed as a negative regulator of adiposity and weight 
gain by increasing lipolysis, inhibiting preadipocyte differentiation, and inducing adipocyte 
apoptosis (222). 
Molecular mechanisms of TNF-mediated inhibition of insulin signaling involve 
serine phosphorylation and transcriptional regulation.  TNF inhibits tyrosine 
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phosphorylation of the insulin receptor and IRS (86), and reduces insulin receptor, IRS-1, 
and GLUT4 expression in adipocytes (233; 255).  One of the best studied inhibitory 
phosphorylation sites is serine 307/312 (rat/human) of IRS-1.  Studies have demonstrated 
that this residue is phosphorylated by a number of kinases including ERK1/2 (79; 236), JNK 
(4; 108), IKK (107), and mammalian target of rapamycin (mTOR) (213).   
Transcriptional inhibition by TNF is accomplished by inhibitory serine 
phosphorylation of persoxisome proliferator-activated receptor (PPAR)  by JNK and ERK 
(2; 184).  The induction of insulin resistance and inhibition of PPAR by TNF can be 
ablated by treatment with thiazolidinediones (TZD) (194; 218; 234).  Additionally, TNF-
induced ceramide production is a critical component of insulin resistance (113), leading to 
inhibition of PKB (269) and decreased CCAAT/enhancer binding protein (C/EBP)  and 
GLUT4 gene expression (89; 174).  Reciprocal positive regulation of both PPAR and 
C/EBP on each other likely leads to a decrease in mRNA abundance.  Because GLUT4 is 
regulated by both PPAR and C/EBP, the decrease in both is likely causal for the 
decrease of GLUT4 in TNF induced insulin resistance.  Further transcriptional regulation of 
insulin resistance by TNF is evidenced by the induction of suppressor of cytokine signaling 
(SOCS) 3, which blocks IRS-1 tyrosine phosphorylation and thus inhibits insulin-stimulated 
glucose uptake (78; 274). 
Interleukin-6 
 Like TNF, IL-6 production is increased in obesity (100; 142; 277) and decreases 
with weight loss (16).  IL-6 signals through the IL-6 receptor which belongs to the class I 
family of cytokine receptors and utilizes Janus kinases (Jak) as intracellular signaling 
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pathways leading to activation of signal transducer and activator of transcription (STAT) 1, 
STAT3, and MAPK (118-119).  IL-6 can act both locally and systemically, and 
approximately 15-35% of circulating IL-6 is adipose tissue derived in humans (195).  In 
human (276), murine (130), and porcine (302) adipocytes IL-6 induces lipolysis. This effect 
can be inhibited by PPAR activation (303).  Additionally, IL-6 induces the expression of 
acute phase proteins (17; 103; 199), a class of proteins secreted predominately by the liver in 
response to inflammation (i.e TNF, IL-6).   
 Literature regarding the ability of IL-6 to induce insulin resistance is much less 
concise.  Similar to TNF, IL-6 induces the expression of SOCS-3 (85; 152), a key 
regulatory feature of Jak/STAT cytokine signaling.  IL-6 also decreases the expression of the 
insulin receptor, IRS, GLUT4, PPAR, and C/EBP (152; 232), and these effects are 
reversed with TZD treatment (152).  Unlike TNF, IL-6 does not induce serine 307 
phosphorylation of IRS-1, at least in adipocytes (232).  However, evidence suggests that IL-6 
signaling can induce inhibitory serine phosphorylation of IRS in other tissues (11; 147; 285). 
C-Reactive Protein 
 CRP is an acute phase protein produced in response to inflammation and tissue 
damage.  CRP is produced predominately by the liver (217), but is also produced by 
adipocytes (43; 210).  Increased expression and circulation of CRP in obesity is likely a 
response to increased adipose tissue production of IL-6 (308).  Increased visceral adipose 
tissue in obesity likely contributes directly to the increase in circulating concentrations of 
CRP.  Indeed, IL-6 is increased in the portal blood of obese individuals, and is correlated to 
circulating concentrations of CRP (94).  Thus, CRP is highly correlated with obesity, insulin 
resistance, the metabolic syndrome, and the development of type 2 diabetes (48; 64; 97; 101).  
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CRP concentrations are negatively correlated with the anti-inflammatory, insulin-sensitizing 
hormone adiponectin (210) and CRP can induce the expression of MCP-1 (215).  
Additionally, mice ubiquitously over-expressing CRP have more adipose tissue macrophages 
and increased adipose tissue expression of MCP-1 and TNF (138).  These effects were only 
seen in high fat diet induced obese mice, not lean controls.  The increase in adipose tissue 
macrophages and increased adipose tissue expression of MCP-1 and TNF in transgenic 
CRP mice is likely a result of increased activation of macrophages and other immune cells.  
In addition to inducing MCP-1 expression (215), CRP activation of leukocytes via FcII 
receptor (CD32) (24) increases CCR2 expression on monocytes (115), the receptor for MCP-
1, leading to increased chemotaxis into adipose tissue.  Moreover, CRP increases 
macrophage proliferation (68), by increased macrophage colony-stimulating factor 
production.  Thus, CRP is produced in response to inflammation, but has the potential to 
further propagate the inflammatory condition. 
Monocyte Chemoattractant Protein 1 
Recruitment of macrophages into adipose tissue in obesity is largely driven by 
chemokines, such as MCP-1 (CCL2).  In obesity, MCP-1 is elevated (36), both in circulation 
and in adipose tissue.  However, increased adipose tissue expression of MCP-1 is not always 
reflected in the circulation (61).  Increased concentrations of circulating MCP-1 is linked to 
both insulin resistance (267) and cardiovascular disease (185).  Knockout of MCP-1 protects 
against macrophage infiltration into adipose tissue, insulin resistance, and ectopic lipid 
deposition (137).  Conversely, adipose specific over-expression of MCP-1 increases adipose 
tissue expression of TNF and IL-6 (136) and macrophage infiltration (136-137), augments 
insulin resistance (136-137) and leads to increased ectopic lipid deposition (137).  Likewise, 
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knockout of the MCP-1 receptor, CCR2, in mice results in fewer adipose tissue macrophages 
and decreased inflammation with reduced insulin resistance and hepatic steatosis (137; 286).  
The importance of MCP-1 in macrophage infiltration is pivotal to the development of insulin 
resistance due to the contribution to inflammation by infiltrating macrophages.  This is 
further evidenced by the amelioration of insulin resistance in db/db mice expressing a mutant 
dominant-negative MCP-1 (267).  Direct contribution of MCP-1 to insulin resistance is less 
clear.  However, pharmaceutical inhibition of MEK attenuates MCP-1 induced insulin 
resistance (136), at least in myocytes.  Potentially, MCP-1 may contribute directly to insulin 
resistance in other tissues in addition to increasing macrophage infiltration. 
Interleukin-8 
 Like MCP-1, IL-8 is a chemokine that induces leukocyte extravasation, primarily 
neutrophils, into tissue during an inflammatory response.  IL-8 serum concentrations are 
increased in obesity and are positively correlated to BMI and negatively associated with 
insulin sensitivity (144).  Additionally, IL-8 is correlated to TNF concentrations in obese 
subjects (257).  IL-8 can be secreted by a number a cell types, and is secreted by adipocytes 
(122) after challenge with lipopolysaccharide (LPS) and by adipocytes from insulin resistant 
subjects (232).  The ability of adipocytes to secrete IL-8 suggests that adipose tissue has the 
potential to recruit neutrophils in obesity due to chronic low-grade inflammation.  Indeed, 
neutrophil infiltration in adipose tissue begins after initial stages of high fat feeding in mice 
(77), and likely precedes macrophage infiltration.  Despite the clear association of IL-8 to 
obesity, the contribution to insulin resistance remains unclear.  Evidence of neutrophil 
infiltration into adipose tissue following initial stages of high fat feeding disappears after 
prolonged feeding (77).  Additionally, circulating IL-8 concentrations paradoxically 
16 
 
increases after weight loss (38), unlike TNF and IL-6, and therefore is not associated with 
improvements in insulin sensitivity following weight loss. 
Adiponectin 
 In addition to inflammatory adipokines, adipose tissue also secretes anti-
inflammatory adipokines such as adiponectin (i.e., Acrp30, AdipoQ, apM1).  Adiponectin is 
a 30 kDa protein produced predominantly by adipocytes (180; 239) and circulates in three 
main forms: trimer, hexamer, and high molecular weight (133).  The predominate nuclear 
receptor for transcriptional control of adiponectin is PPAR (126).  Additionally, PPAR 
transcriptionally represses the expression of ERp44 (173), which inhibits the secretion of 
adiponectin from adipocytes (280).  Unlike other adipokines, adiponectin is decreased in 
obesity, insulin resistance, and cardiovascular disease and is negatively correlated with BMI 
(12; 211).  Treatment of human, porcine, and murine macrophages with adiponectin 
attenuates LPS-induced activation of NFB and TNF production (293; 297; 305).  
Additionally, adiponectin induces the production of the anti-inflammatory cytokine 
interleukin-10 (IL-10) in porcine macrophages (293).  Similar to macrophages, adiponectin 
attenuates activation of NFB and expression of TNF and IL-6 in adipocytes (5). 
 Perturbed glucose homeostasis caused by insulin resistance can be further impaired 
by decreased concentrations of the anti-diabetic adipokine, adiponectin.  Experimental 
evidence in adiponectin knockout mice suggests that adiponectin is important in protecting 
against the development of insulin resistance (150; 202).  Adiponectin signals through two 
receptors, AdipoR1 and AdipoR2, which are differentially expressed on multiple cell types 
(299).  Targeted receptor disruption has demonstrated that AdipoR1 and AdipoR2 signaling 
activates AMP-activated protein kinase (AMPK) and PPAR (301) , respectively.  The 
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insulin-sensitizing effects of adiponectin mediated by activation of AMPK and PPAR 
include stimulation of glucose uptake and fatty acid oxidation, and inhibition of lipogenesis 
and gluconeogenesis (46; 57; 272; 292; 295; 298; 300-301; 306).  
Oxidative Stress 
 Another mechanism of obesity-related insulin resistance includes oxidative stress, 
which is the generation of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS).  Oxidative stress is closely linked with obesity and type 2 diabetes (13; 19; 26).  
There are a multitude of ROS and RNS that are generated by NADPH oxidase (20), nitric 
oxide synthase (214), mitochondrial electron transport (312), and cytochrome P450 (309) in 
response to stimuli such as TNF (59), endoplasmic reticulum stress (112), insulin (149), 
and excess nutrients.  Oxidative stress induced with hydrogen peroxide in vitro has increased 
activation of JNK and IK, increased serine 307 and 632 phosphorylation of IRS-1, and 
decreased PI3K activity (25).  Additionally, oxidative stress decreases GLUT4 expression in 
adipocytes (219; 235), thus potentially decreasing insulin stimulated glucose uptake. 
Metabolic Endotoxemia 
 A phenomenon known as metabolic endotoxemia is another contributing factor the 
development of insulin resistance in obesity.  Metabolic endotoxemia is a sub-clinical 
increase in serum endotoxin, or LPS.  LPS initiates a classical immune response via the 
activation of toll-like receptor 4 (Tlr4), which leads to the production of mediators of 
inflammation such as TNF and IL-6.  Metabolic endotoxemia is positively correlated with 
energy intake (8). Consumption of lipids induces postprandial endotoxemia and increases 
circulating IL-6 (80; 160).  Additionally, sub-clinical endotoxemia in humans induces 
adipose tissue inflammation and transient insulin resistance (190).  As such, metabolic 
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endotoxemia is associated with an increased risk for the development of type 2 diabetes 
(224). 
Obesity and Adipose Tissue Macrophages 
Nearly a decade after the link between obesity, inflammation, and insulin resistance 
was established (123), two laboratories independently discovered that obesity is associated 
with macrophage accumulation in adipose tissue (287; 296).   Both body mass and adipocyte 
size are positively correlated with the number of macrophages present in adipose tissue 
(287).  In addition to the increase in the number of macrophages, their localization and 
function change in obese individuals (177).  Once within adipose tissue, macrophages recruit 
more macrophages in a feed forward fashion (206), which increases the inflammatory state 
and contributes directly to insulin resistance, the metabolic syndrome, and the development 
of type 2 diabetes. 
Human adipose tissue macrophages are characterized via flow cytometry by their 
expression of CD14, the co-receptor for Tlr4, and CD206, a mannose receptor (310), which 
distinguishes macrophages from contaminating blood monocytes.  Adipose tissue 
macrophages express high levels of the scavenger receptors CD163 and CD36, do not 
express the T-cell co-stimulation receptors CD40, CD80, and CD86, and express only low 
levels of the integrin CD11c (310).  One study demonstrated that macrophages expressing 
CD11c are present in ‘crown-like structures’ surrounding necrotic adipocytes and are 
involved in lipid uptake (289), consistent with phagocytic activity.  Additionally, adipose 
tissue macrophages produce high concentrations of IL-1, IL-6, IL-8, IL-10, TNF, and 
MCP-1 (31; 310).  Adipose tissue macrophages can also be separated into subpopulations by 
the expression of CD16, an Fc III receptor, with the majority being CD16- (31).  However, 
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the inflammatory gene expression between CD16
+
 and CD16
-
 adipose tissue macrophages 
differs only by higher expression of MCP-1 and IL-6 in CD16
-
 macrophages (31).  The 
presence of CD16
-
 macrophages in adipose tissue may reflect infiltrating monocytes from the 
circulation (31), as blood CD16
-
 monocytes express CCR2, the receptor for MCP1 and 
CD62L (109; 265).  However, this has not been definitively proven in regards to adipose 
tissue macrophages. 
Macrophages can be classified into two broad functional subpopulations, which 
parallels the polarization of naïve CD4+ T-lymphocytes toward either a Th1 or Th2 immune 
response.  The first is classically-activated (M1) macrophages.  Activation by interferon or 
LPS in a manner consistent with a Th1 immune response characterize the phenotype of M1 
macrophages.  These cells produce high amounts of TNFand express inducible nitric oxide 
synthase (iNOS).  The second is alternatively-activated (M2) macrophages.  Activation by 
IL-4 or IL-13 in a manner consistent with a Th2 immune response characterizes the 
phenotype of M2 macrophages. These cells produce high amounts of IL-10, and express 
arginase instead of iNOS.  In adipose tissue, resident macrophages display the M2 
phenotype.  Adipocyte hypertrophy and dysregulation leads to the monocyte diapedesis to 
adipose tissue.  These infiltrated macrophages are of the M1 phenotype.  These two 
subpopulations of macrophages and their functions in adipose tissue are well reviewed by 
others (50; 62; 198; 243). 
From the initial reports in 2003 by Weisberg et al. (287) and Xu et al. (296), it has 
been evident macrophages play a pivotal role in the progression of obesity as a state of 
chronic low-grade inflammation.  Much of the research regarding adipose tissue 
macrophages has been done in mouse models, including macrophage M1 and M2 
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polarization.  While the M1/M2 phenotype is a useful starting point, human macrophage 
heterogeneity as well as differences between murine and human macrophages emphasizes the 
need for alternate immunological models to study macrophage function in relation to obesity.   
Macrophage infiltration into adipose tissue is largely driven by MCP-1 and its 
receptor CCR2.  CRP is a acute phase protein that interacts with FcII receptor (24) and 
increases CCR2 expression on monocytes (115), as well as induces the expression of MCP-1 
(215).  However in mice, CRP is not an acute phase protein and is not highly expressed 
(264), while it is in humans and swine.  The lack of CRP functionality in mice does not 
abrogate the importance of MCP1 and CCR2 in mice models of obesity, as it is evident that 
they are intricately involved in macrophage infiltration in mice (136-137; 286), but it clearly 
demonstrates a difference in the etiology of chronic inflammation in obesity between mice 
and humans. 
Probably most notably is the difference between human and murine macrophages is 
nitric oxide (NO) production via iNOS.  Unlike murine macrophages, human macrophages 
do not produce NO in response to stimuli (192; 231; 270), which is characteristic of M1 
macrophages.  Consistent with human macrophages, porcine bone marrow-derived 
macrophages do not produce NO in response to LPS (139).  Additionally, porcine bone 
marrow-derived macrophages up-regulate genes in response to LPS similar to human 
macrophages, and that are not up-regulated by murine macrophages.  These genes include 
IDO, STAT4, CCL20 as well others.  For further review of similarities and differences 
between pig and human macrophages, please refer to a review by Fairbairn et al. (82). 
Recently, phenotypical characterization of Yorkshire swine adipose tissue 
macrophages was performed by flow cytometry (84).  Using the mature macrophage marker 
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CD203a to indentify macrophages, subcutaneous adipose tissue macrophages were 
predominately CD163+, CD16+, and CD14+ (Table 1).  It is difficult to make direct 
comparisons to human adipose tissue macrophages, because the human cells were 
characterized by being CD14
+
 in conjunction with CD206
+
 (310).  Swine adipose tissue 
macrophages are only 80% CD14+ (84).  Potentially, the previous studies focusing on human 
adipose tissue macrophages disregarded populations that are CD14
-
.  Although swine adipose 
tissue macrophages express higher levels of CD16 (Table 1) than humans macrophages do 
(31), they may still be a valuable resource for investigating the function of macrophages in 
adipose tissue given the greater differences between mice and human macrophages.   
Obesity and Fatty Acids 
 Multiple studies have demonstrated an association between obesity and increased 
circulating free fatty acids (121; 223; 227).  A contributing factor to elevated circulating free 
fatty acids is increased adipose tissue lipolysis (1; 120; 153; 230), due in part to the 
decreased anti-lipolytic effect of insulin.  The detrimental effects can be evidenced by the 
induction of insulin resistance in lean human or rats when infused with free fatty acids (164; 
166).  
 The pathological consequences of increased circulating free fatty acids extend to the 
activation of Tlr4, an event that further propagates chronic inflammation associated with 
obesity.  LPS recognition by Tlr4 is accomplished through the lipid A moiety (225), which 
contains saturated fatty acids.  Early work by Daniel Hwang’s laboratory determined that 
lauric acid induced cyclooxgenase 2 expression in RAW 264.7 macrophages via the 
activation of Tlr4 and NFB (163).  In adipocytes, treatment with saturated fatty acids 
induces inflammation including the activation of JNK and NFB as well as the production of 
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IL-6 and TNF (6; 32; 67; 252; 260).  Additionally, in vivo, the absence or loss-of-function 
of Tlr4 protects against high saturated fat induced inflammation and insulin resistance (66; 
245; 273).  There is also evidence that Tlr2 is involved in saturated fatty acid induced 
inflammation (65; 67; 76) 
Beyond Tlr4, saturated fatty acids can induce inflammation and insulin resistance via 
ceramide production.  Lipolysis can induce inflammation via activation of JNK and p38 
MAPK pathways.  Inhibition of ceramide synthesis blunts this activation (200) in adipocytes.  
Moreover, inhibition of fatty acid synthase in adipocytes decreases NFB activation (6) 
through the inhibition of ceramide synthesis.  Similarly in monocytes, inhibition of ceramide 
synthesis reduces JNK, ERK, and p38 MAPK activation due to saturated fatty acid treatment 
(240). 
Circulating saturated free fatty acids are positively correlated with circulating IL-6 
concentrations (87) and negatively correlated with circulating adiponectin (88).  Conversely, 
n-3 fatty acids are inversely associated with circulating cytokines (90; 134; 193), including 
CRP, IL-6, and TNF.  The major n-3 fatty acids with biological activity are 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  These fatty acids are readily 
available from oily marine fish or can be synthesized in vivo from -linolenic acid.  
However, it is estimated that only 6% of -linolenic acid may be converted to EPA or DHA 
in vivo (169).  The fate of consumed n-3 fatty acids include incorporation into triglycerides 
and storage in adipose tissue, incorporation into phospholipids to form part of the cellular 
membrane, circulation as free fatty acids complexed with albumin, or oxidized for energy. 
Several studies have demonstrated the immunosuppressive potential of n-3 fatty acids 
in multiple cell types including T cells, monocytes, macrophages, dendritic cells, and 
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adipocytes (6; 124; 205; 311; 313).  Observational studies demonstrate a beneficial 
relationship between n-3 fatty acid intake and obesity, but data from cross-sectional studies 
are limited (39).   In rodents, n-3 fatty acids decrease adipose tissue inflammation, 
macrophage infiltration, and insulin resistance as well as increase circulating adiponectin (91; 
125; 135; 271).  In swine, EPA and DHA attenuate LPS induced febrile response and 
circulating TNF (104).   Molecular mechanisms of inhibition of inflammation by n-3 fatty 
acids include alterations in lipid rafts (256; 284), altered eicosanoid production (14; 251), 
inhibition of NFB (6; 162; 314), and activation of PPAR(15; 207).   
Swine Models of Obesity 
Swine are increasingly being used as a biomedical research model, in large part due 
to their similar physiology and anatomy to humans (170).  In the context of obesity and 
metabolic syndrome, swine have been used to study cardiovascular disease (22; 27-29; 33; 
58; 75; 106; 110; 154; 188; 196; 201; 203; 216; 229; 261; 294), genetic analysis (83; 95-96; 
114; 179; 208; 212; 263; 291), drug testing (42; 226; 304; 315), pancreas function (102; 155; 
157), dietary components (34; 221; 228-229; 238), steatohepatitis (21; 165), renal function 
(47; 168; 171), insulin signaling (161),  and exercise training (58; 75). 
 Commercial swine fed diets high in fat and cholesterol have been used to study 
diabetes accelerated atherosclerosis (110; 201; 261).  These swine developed 
hypercholesterolemia, but had normal circulating concentrations of glucose and triglycerides.  
Development of diabetes by treatment with streptozotocin was required to induce 
hyperglycemia.  Additionally, streptozotocin exacerbated the progression of atherosclerosis 
in this model.  Consumption of high fat diets by commercial swine increases abdominal fat, 
weight gain, and results in hypertension and hypercholesterolemia (106).  However, it does 
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not significantly affect insulin sensitivity or increase circulating concentrations of CRP (106).  
As mentioned previously, increased circulating free fatty acids and sub-clinical endotoxemia 
are physiological responses associated with obesity.  In commercial swine, experimental 
endotoxemia and increased circulating concentrations of free fatty acids did not affect 
glucose homeostasis, but did decrease circulating growth hormone concentrations (40), 
which may increase adipose tissue mass and decrease lean mass.    
 Commercial swine have also been used to study the effect of consumption of different 
fats on body composition and metabolic parameters.  Saturated fats (lard), mono-unsaturated 
fats (olive oil), and sucrose consumption increased whole-body adiposity, but only the mono-
unsaturated fat increased visceral adiposity (238).  Consumption of either saturated or mono-
unsaturated fat, but not sucrose, decreased insulin sensitivity (238).  Another study evaluated 
the effect of the consumption of saturated fats (lard) and polyunsaturated fats (canola oil) on 
metabolic markers and inflammation.  Neither fat source altered circulating IL-6 or CRP 
concentrations, increased adipose tissue macrophages, or altered insulin sensitivity; although 
the saturated fat induced hypercholesterolemia (34).  Differences in the ability of commercial 
swine to develop dietary induced changes in insulin sensitivity may be affected by the age 
that dietary treatment was initiated.  Sabin et al. (238) began treatment at one week of age, 
Galili et al. (106) began treatment at 3 months of age, and Braucher (34) began treatment at 
18 weeks of age.  Increased age of initial dietary treatments may reduce the negative effects 
of dietary fat on insulin sensitivity.   
Although commercial swine have been used in obesity-related research, common 
genetic selection for lean growth limits the potential of this model.  Ossabaw swine, 
however, are a promising model for obesity research, and have already been extensively used 
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in cardiovascular disease and steatohepatitis research (22; 27-29; 74-75; 154; 165; 203; 216).  
Ossabaw swine were isolated for ~500 years on Ossabaw Island, just off the coast of 
Georgia, USA (187). The introduction of new genetics has been limited, but includes one 
Hampshire boar in the mid 1970s (187).  This genetic isolation allowed for the development 
of a “thrifty genotype” to survive the famine and feast environment.  Because of this unique 
adaptation, Ossabaw swine can store more fat on a kg body weight basis than any other non-
domesticated mammal (258).  
 Ossabaw swine are smaller, slower growing, and have decreased muscle mass 
compared to domestic swine (41; 60; 182).  Increased fat storage and decreased muscle mass 
in Ossabaw swine may be due to decreased growth hormone secretion in response to insulin 
(283), but not hyperphagia (281).  Ossabaw swine have impaired glucose tolerance (282) and 
hypertriglyceridemia and hypercholesterolemia (81) as well as a higher capacity for 
gluconeogenesis, glycolysis, and lipogenesis than lean swine (183). 
 The aforementioned information regarding Ossabaw swine was collected in the 
1970s.  Recently, growing concern about the obesity and diabetes epidemic sparked new 
interest in Ossabaw swine and a breeding colony was established by Michael Sturek (262). 
Phenotypically, Ossabaw swine display many of the same characteristics today as they did in 
the 1970’s.  Upon development of obesity, they develop hypercholesterolemia (23; 27; 29; 
56; 71; 74; 148; 159; 165; 168; 175; 203; 216), hypertriglyceridemia (27; 29; 71; 74; 148; 
165; 216), impaired glucose tolerance (74; 159; 203), hyperglycemia (27; 29; 165; 216), and 
hyperinsulinemia (27; 29; 71; 165).  It is important to note that in addition to high fat content, 
some of the diets contained supra-physiologic amounts of cholesterol (23; 27; 29; 33; 56; 74; 
148; 159; 165; 168; 175; 203; 216), which may augment the dyslipidemia in this model.   
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Only one study showed a decrease in serum adiponectin, marked hyperlepinemia, and 
systemic inflammation upon prolonged consumption of a high fat diet (165). 
 Ossabaw swine contain a mutation in the 3 subunit of AMPK (172).  This mutation 
(V224I) is a Val
199→Ile missense mutation that causes low muscle glycogen and increased 
intramuscular fat (10; 55).  This mutation is consistent with the increase in intramuscular 
lipid seen in obese Ossabaw swine (56).  It has been hypothesized by Shen et al. that this 
mutation may be causal in the development of insulin resistance in Ossabaw swine (244).  
However, to this date this has not been investigated. 
 Another common swine model is the Yucatan minipig.  Yucatan swine originate from 
the Yucatan Peninsula of Mexico.  When Yucatan swine are fed a high fat high, cholesterol 
diet, they develop hypercholesterolemia (72; 111; 196; 209; 290), but do not exhibit 
decreased insulin sensitivity in response to an insulin challenge (209).  Yucatan swine do not 
readily develop hyperglycemia upon consumption of a western diet (30; 72; 196; 209; 241; 
290), but do have a decreased glucose infusion rate during the hyperinsulinemic-euglycemic 
clamp (241).  Additionally, Yucatan swine fed a high fat high cholesterol diet have higher 
liver content of cholesterol, cholesteryl esters, and triglycerides (72), as well as increased 
visceral adiposity (290).  When fed a western diet, Yucatan swine develop hyperleptinemia 
(241; 290) and have increased adipose tissue expression of leptin and  IL-6 (241).  Whereas 
previous studies in Yucatan swine showed only hypercholesterolemia and minimal effect on 
glucose homeostasis; more recently Yucatan swine have been shown to develop increased 
circulating concentrations of triglycerides and NEFA, as well as hypercholesterolemia after 
long-term consumption of a high fat diet (161).  In addition, these swine develop 
hyperglycemia, hyperinsulinemia, and impaired myocardial insulin signaling (161).  
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Differences between these studies may be attributable to varying genetics between breeding 
herds. 
 Göttingen minipigs are another swine model that are used to study obesity and its co-
morbidities.  Göttingen swine were developed in the 1960s in Göttingen, Germany by cross 
breeding between Vietnamese swine, Hormel swine, and the German improved Landrace 
(156).  Gottingen swine fed a high fat diet have increased body fat (132; 158; 275), plasma 
cholesterol (158) and triglycerides (132).  Göttingen swine display insulin resistance after 3-5 
months of high fat feeding (158; 275), as well as hyperinsulinemia in response to an 
intravenous glucose tolerance test after as little as 5 weeks of high fat feeding (132).  
However, impaired fasting glucose was only seen in one study (158).  Additionally, there is a 
sexual dimorphism in the susceptibility of Göttingen swine to negative metabolic effects 
during diet-induced obesity.  Female Göttingen swine become more obese, have a greater 
degree of insulin resistance, and a more atherogenic plasma profile (i.e. cholesterol, 
triglycerides) than their male counterparts (52).  Higher concentrations of both testosterone 
and estradiol (52) in male Göttingen swine may reduce their risk for obesity-associated co-
morbidities (51). 
 In addition to Ossabaw, Yucatan, Göttingen, and commercial swine, there are several 
Chinese swine that have been used in obesity research.  These include Guizhou, Ningxiang, 
Bama, Wuzhishan, and Nongda swine.  When fed a high fat, high sucrose diet, Guizhou 
swine have increased body weight gain and increased fat deposition (294; 304).  These swine 
develop dyslipidemia (294; 304) , hyperglycemia (294), and display insulin resistance as 
evidenced by both an insulin challenge and an oral glucose tolerance test (294; 304).  
Additionally, ectopic lipid deposition is evident in the liver, pancreas, and muscle after long 
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term dietary treatment (294; 304).  Moreover, Guizhou swine have increased circulating 
concentrations of TNF after long-term dietary treatment (294).  The genetically obese 
Chinese Ningxiang swine may have potential as an obesity model.  Compared to lean 
commercial swine Ningxiang have higher circulating concentrations of insulin and 
cholesterol, as well as greater adipose tissue and less lean mass percentage (117).  In a direct 
comparison of Bama, Wuzhishan, and Nongda swine, only the Bama and Wuzhishan swine 
developed hyperglycemia in response to a high fat and high sucrose diet (49).  Additionally, 
Bama swine fed a high fat, sucrose, and cholesterol diet developed hyperglycemia, 
hyperinsulinemia, hypercholesterolemia, and also had decreased circulating concentrations of 
IGF-1 (167). 
 While rodent models have been a pillar to obesity research, they do not consistently 
develop three or more of the risk factors of the metabolic syndrome (253).  The ability of 
Ossabaw and Yucatan swine to develop features of metabolic syndrome has been compared 
by Neeb et al. (203).  Yucatan swine only develop hypercholesterolemia, while Ossabaw 
swine develop obesity, insulin resistance, glucose intolerance, hypertriglyceridemia, 
hypercholesterolemia, and hypertension (203).  Additionally, as reviewed above, Ossabaw 
swine consistently develop more risk factors for the metabolic syndrome than other swine as 
breeds.  While Ossabaw swine do develop obesity and insulin resistance, adipose tissue 
inflammation has yet to be evaluated in this breed, or any other breed.  Only one study 
demonstrated increased systemic inflammation in Ossabaw swine (165), but did not evaluate 
adipose tissue inflammation.  Chronic low-grade inflammation is a hallmark of obesity and 
thus, needs to be evaluated in Ossabaw swine to further the development of the model. 
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Summary 
 The prevalence of obesity and its co-morbidities continues to rise in the United States 
and other developed countries.  Excess caloric intake causes adipose tissue expansion 
through adipocyte hypertrophy and hyperplasia.  Adipocyte hypertrophy leads to adipose 
tissue dysfunction causing increased production of inflammatory adipokines (i.e. IL-6, 
TNF, MCP-1) and a decrease in anti-inflammatory adipokines (i.e. adiponectin).  These 
events lead to macrophage infiltration into adipose tissue, propagating inflammation and 
creating a chronic state of low-grade inflammation that is often associated with obesity.  The 
increased production of inflammatory adipokines by adipocytes and macrophages, as well as 
oxidative stress induces adipose tissue insulin resistance via the activation of NFB and 
MAPK pathways.  Free fatty acids released from adipocytes due to insulin resistance, as well 
as from the breakdown of necrotic adipocytes by macrophages causes ectopic lipid 
deposition, particularly in muscle, liver, and pancreas.  Ectopic lipid deposition, in 
conjunction with increased systemic inflammation from adipokines, can lead to insulin 
resistance in the liver and muscle and decrease pancreatic insulin secretion.  These events can 
lead to the eventual development of type 2 diabetes mellitus. 
 The susceptibility to obesity is influenced by multiple factors including genotype, 
environment, and poor diet.  Dietary factors, such as fatty acids, have potential implications 
in obesity.  Saturated fatty acids are linked to the inflammatory profile in obese individuals.  
Saturated fatty acids can activate Tlr4, activating NFB and MAPK pathways and thus, 
increasing inflammation.  Additionally, consumption of saturated fatty acids can contribute 
to metabolic endotoxemia.  Conversely, the n-3 fatty acids EPA and DHA are anti-
inflammatory in nature and are negatively correlated to the inflammatory profile in obese 
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individuals.  EPA and DHA increase PPAR activation and adiponectin production, and 
decrease NFB activation. 
 Largely because of comparative physiology and anatomy, the use of swine for 
research involving obesity and its co-morbidities has increased.  Ossabaw swine in particular 
become obese when adequate food is available and develop multiple risk factors of the 
metabolic syndrome including insulin resistance.  However, adipose tissue inflammation has 
not been investigated in this model.  Macrophage infiltration and function in adipose tissue is 
of particular interest due to immunological discrepancies between mice and human, 
especially regarding CRP function and NO production by macrophages.  Swine are a more 
relevant immune model for humans, but needs further evaluation. Based upon the literature 
outlined above, I sought to characterize adipose tissue inflammation in Ossabaw swine in 
response to saturated and n-3 fatty acids and to determine specific genes involved in adipose 
tissue expansion by diet-induced obesity to further validate Ossabaw swine as a model for 
human obesity and obesity-linked inflammation. 
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Tables 
Table 1.  Swine subcutaneous adipose tissue macrophage phenotype
a
. 
Marker Mean (%) SEM 
CD203a+ 26.94 2.29 
 
CD163
+
 69.82 1.12 
  
CD14
+
CD16
+
 67.64 2.60 
  
CD14
+
CD16
-
 20.17 2.37 
  
CD14
-
CD16
+
 7.52 0.25 
  
CD14
-
CD16
-
 4.66 0.38 
 
CD163
-
 30.18 1.12 
  
CD14
+
CD16
+
 41.15 1.41 
  
CD14
+
CD16
-
 21.99 0.81 
  
CD14
-
CD16
+
 12.32 0.41 
    CD14
-
CD16
-
 24.54 1.15 
a
Adapted from Faris et al. (84). 
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Abstract 
Fatty acids have distinct cellular effects relating to inflammation and insulin 
sensitivity.  Dietary saturated fat activates toll-like receptor-4 which can lead to chronic 
inflammation, insulin resistance, and adipose tissue macrophage infiltration.  Conversely, n-3 
fatty acids are generally anti-inflammatory and promote insulin sensitivity, in part via 
through peroxisome proliferator-activated receptor- Because Ossabaw swine are an 
attractive biomedical model, we fed Ossabaw pigs either a low fat control (LFC), high fat 
palm oil (HFP), or high fat palm oil with n-3 fatty acids (HFPn3) diet for 30 weeks to 
investigate the effect of saturated fats and n-3 fatty acids on obesity-linked inflammatory 
markers.  There was no diet-related induction of the inflammatory markers C-reactive 
protein, tumor necrosis factor-, interleukin-6 or interleukin-12. The increase in 
inflammatory adipose tissue CD16
-
CD14
+
 macrophages by high palm oil was attenuated by 
n-3 fatty acids.  Both high fat diets induced hyperglycemia, without hyperinsulinemia.  
Insulin sensitivity was decreased in the HFP group, but not the HFPn3 group during an 
insulin challenge.  This effect was not mediated by decreased phosphorylation of PKB.  
Thus, in a porcine model of obesity, n-3 fatty acids partially attenuate insulin sensitivity, but 
only marginally change inflammatory status and macrophage phenotype in adipose tissue.   
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Introduction 
Obesity is accompanied by chronic inflammation in adipose tissue, increased 
circulating concentrations of tumor necrosis factor- (TNF), interleukin-6 (IL-6), and C-
reactive protein (CRP), and decreased concentrations of adiponectin (2).  This chronic 
inflammation links obesity and the development of insulin resistance (39).  Dietary saturated 
fatty acids promote obesity in part through the induction of inflammation via activation of 
toll-like receptor-4 (i.e., tlr4, the innate immune receptor for lipopolysaccharide) (28).  
Absence of functional tlr4 in mice reduces circulating proinflammatory cytokine 
concentrations and decreases macrophage infiltration into adipose tissue in high fat diet-
induced obesity (8; 28; 32).  Furthermore, in 3T3 L1 mouse adipocytes, palmitate activates 
nuclear factor B (NFB),  protein kinase C, and mitogen-activated protein kinase, all of 
which increase inflammatory cytokine production (1).   
For individuals consuming a diet high in saturated fat, a major determinant of health 
is the n-6:n-3 (fatty acids, omega-6:omega-3) (5-6).  Unlike saturated fatty acids, the n-3 
polyunsaturated fatty acids (PUFA) eicosapentanoic acid (EPA) and docosahexanoic acid 
(DHA) exert predominantly anti-inflammatory effects, as is evident in that DHA antagonizes  
NFB activation by palmitate in 3T3 L1 adipocytes (1).  In mice, EPA prevents or reverses 
hyperinsulinemia, hyperglycemia, and increased circulating monocyte chemotatic protein-1 
(MCP-1) (16), and also decreases infiltration of adipose tissue with macrophages (30).  
Moreover, n-3 PUFA alleviate the decline in serum adiponectin associated with obesity (12; 
15; 30), and EPA decreases serum CRP in diabetic patients (26).   
Physiological differences between rodents and humans underscore the need for 
comparative models in biomedical research, and the pig is emerging rapidly as an attractive 
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model for energy metabolism and obesity.  Like humans, pigs are natural omnivores, rely on 
apo B-100 to shuttle cholesterol in the LDL fraction, and have minimal brown fat retention 
postnatally.  Furthermore, adipose depots in pigs are of sufficient size that multiple assays 
can be carried out on adipocytes or stromal vascular cells without pooling across depots or 
animals.  Although Ossabaw swine have been used as a model for metabolic syndrome, 
cardiovascular disease, coronary artery disease, and steatohepatisis (11; 20; 24), very little is 
known about adipose inflammation in this model.  Consequently, we sought to characterize 
obesity-linked inflammatory markers in the adipose tissue of this novel model, and to test the 
hypothesis that adding n-3 PUFA to a diet high in saturated fat will attenuate chronic 
inflammation, protect against diet-induced insulin resistance, and alter phenotypical changes 
in adipose tissue macrophages. 
Methods 
Animals and Diets. All animal procedures were conducted at Iowa State University 
and were approved by the Iowa State University Institutional Animal Care and Use 
Committee.  Two groups (27 total) of mature male and female Ossabaw swine (Sus scrofa) 
(initial body weight 47.4 ± 0.3 kg) were housed in individual pens in a temperature 
controlled environment with a 12 hour light cycle.  Swine were obtained from the 
Comparative Medicine Program at the Indiana University School of Medicine and Purdue 
University from a herd that tested negative for Brucella spp. and psuedorabies, and showed 
no clinical evidence of communicable disease upon arrival or during the study.  Animals 
were assigned to one of three dietary treatments: a low fat control diet (LFC, n=9; 3 male and 
6 female), a high fat palm oil diet (HFP, n=9; 2 male and 7 female), and a high fat palm oil 
diet with n-3 supplementation (HFPn3, n=9; 2 male and 7 female) (Table 2).  Three pigs in 
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the HFPn3 dietary treatment died during the study.  Autopsy results indicated that the pigs 
did not have any obvious signs of disease. It was noted that severe congestion in the lungs 
would support a heart condition that was acute and fatal.  However, the exact cause of death 
was unknown.  The HFP and HFPn3 diets were fed ad libitum and the LFC diet was 
restricted to maintain a mature lean body weight. The “healthy” control diet (Table 2) was 
designed to limit caloric intake and provide adequate n3 fatty acids through modest 
inclusions of fish meal, canola oil, and n3 fatty acid supplement (Gromega
TM
 365).  Both 
high fat diets were high in saturated fatty acids and formulated to be isocaloric.  Canola oil 
and the n3 fatty acid supplement was used to reduce the n6:n3 to be comparable with the 
control diet.  Body weight and feed intake were measured weekly.  To confirm the fatty acid 
profile of each diet, lipids were extracted by the method of Lepage and Roy (21).  Fatty acid 
methyl esters were analyzed by gas chromatography (model 6890; Hewlett-Packard, Palo 
Alto, CA) fitted with an Omegawax 320 (30 m x 0.32 mm internal diameter, 0.25 m) 
capillary column (Sigma-Aldrich, St. Louis, MO).  The injector and detector temperatures 
were 250°C, and the oven temperature was 200°C.   
Insulin Challenge and Tissue Collection.  After 30 weeks of dietary treatment, 
animals were fasted for 12 hours overnight and were anesthetized with 
telazol:ketamine:xylazine (1:1:1).  Thereafter, blood pressure and mean arterial pressure were 
taken with an oxillometric blood pressure monitor (Cardell, CAS Medical Systems, Inc., 
Branford, CT) with a 9 cm cuff on the metatarsus.  Each measurement was taken three times 
and averaged. Blood was collected via jugular venipuncture and then animals were 
challenged with 0.25 IU/kg of porcine insulin (MP Biomedicals, Solon, CA) intravenously as 
adapted from Xi et al. (37).  Glucose measurements were taken from blood obtained by ear 
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pricks at 0, 5, 10, and 15 minutes post insulin challenge using a glucometer (LifeScan, 
Milpitas, CA).  Pigs were then killed by exsanguination.  Subcutaneous (SQ) adipose tissue 
from back fat above the 10
th
 rib, visceral adipose tissue (VIS) from the ventral intra-
abdominal cavity, omental adipose tissue (OM), liver, and longissimus dorsi (LD) from 
above the 10
th
 rib were collected.  Liver and LD were snap frozen in liquid nitrogen.  
Adipose tissue was divided two ways: snap frozen in liquid nitrogen or stored in ice cold 
PBS with 0.2% BSA for transport to the laboratory and the isolation of stromal vascular cells 
(SVC).   
SVC were isolated from adipose tissue as follows: adipose tissue was minced finely 
with a razor blade and digested in Hank’s Buffered Salt Solution (HBSS) with 20 mM 
HEPES (pH 7.4), 3% BSA, and 2 mg/mL Collagenase Type I (Worthington-Biochemical 
Corporation, Lakewood, NJ) for 45 minutes, 125 rpm, at 37°C.  Samples were then 
centrifuged for 5 min at 1000xg and the supernatant was discarded.  The pellet was dissolved 
in 10 mL of RBC lysis buffer (0.154 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.3) for 
5 min to lyse red blood cells, and then 10 mL of PBS was added and samples were passed 
through a 100 m filter.  The filtrate was centrifuged for 5 min at 1000xg and the pellet was 
resuspended in HBSS with 20 mM HEPES (pH 7.4). 
Flow Cytometry.  Up to 1 x 10
6
 SVC were washed in 2 mL of fluorescence-activated 
cell sorting buffer (FACS, 0.1% sodium azide, 0.1% BSA in PBS).  Cells were treated with 
10 L of pig serum for 15 min at 4ºC to prevent nonspecific binding.  Cells were then 
incubated with 10 L of anti-CD203a IgG1 (1:20) (Mybiosource, LLC, San Diego, CA) or 
isotype control (mouse IgG1, ) (eBioscience, Inc., San Diego, CA) for 15 minutes at 
4ºC and then washed in 2 mL of FACS buffer.  Cells were next incubated in 10L of goat-
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anti mouse IgG1-FITC (1:50) (SouthernBiotech, Birmingham, AL) for 15 min at 4ºC and 
then washed in 2 mL FACS buffer.  Cells were incubated in 10 L of biotinylated anti-CD16 
(1:50) (BD Pharmingen, San Diego, CA) or isotype control (biotinylated mouse IgG1, 
) (BD Pharmingen) for 15 min at 4ºC and then washed in 2 mL of FACS buffer.  Cells 
were then incubated in 10 L of Streptavidin-Peridinin Chlorophyll-a Protein-Cy5.5 (1:50) 
(BD Pharmingen) and 10 L of anti-CD14-PE (1:20) (Antigenix America, Huntington 
Station, NY) or isotype control (PE mouse IgG2b, ) (BD Pharmingen) for 15 minutes 
at 4ºC and then washed in 2 mL of FACS buffer.  Cells were then fixed in 200 L of 1% 
paraformaldehyde and stored at 4ºC until analysis.  Analysis was performed on a BD 
FACScanto flow cytometer (Becton Dickinson, San Jose, CA), and data was analyzed using 
FlowJo software V8.5.2 (Tree Star, Inc., Ashland, OR). 
Serum and Tissue Analyses.  Cholesterol, triglycerides, and non-esterified fatty acids 
(NEFA) were analyzed using Chol Slides (Ortho Clinical Diagnostics, Rochester, NY), Trig 
Slides (Ortho Clinical Diagnostics), and NEFA-HR (Wako Diagnostics, Richmond, VA), 
respectively, on a Vitros 5.1 Chemistry Analyzer (Ortho Clinical Diagnostics).  Serum 
insulin and CRP concentrations were measured by EIA and ELISA, respectively (ALPCO, 
Salem, NH).  Serum TNF, IL-6, IL-10 and IL-12p40 concentrations were measured by 
ELISA (R & D Systems, Minneapolis, MN).  The HOMA-IR was calculated using fasting 
serum insulin (U/mL) x fasting blood glucose (mg/dL) divided by 405 (23).  Plasma 
homocysteine concentrations were determined by HPLC as described by Williams et al. (36).  
Total liver and LD lipid content was determined by the method of Folch et al. (13).   
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Whole frozen tissue samples were pulverized and homogenized in ice cold buffer (50 
mM HEPES pH 7.4, 150 mM NaCl, 10 mM sodium pyrophosphate, 10 mM NaF, 5 mM 
EDTA, 1 mM MgCl2, 1 mM CaCl2, 2 mM Na3VO4, 2 mM phenylmethylsulfonyl fluoride, 5 
g/mL aprotinin, 5 g/mL leupeptin, 5 g/mL pepstatin, 10% glycerol, and 1% Triton X-
100).  Homogenates were mixed by shaking for 45 min at 4°C and then centrifuged at 
10,000xg for 20 min at 4°C.  The supernatants were collected and the protein concentration 
was determined using BCA reagent (Pierce, Rockford, IL).   
Samples were added to a reducing loading buffer with a final concentration of 50 mM 
Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 5% -mercaptoethanol, and 0.005% bromophenol 
blue and heated for 10 min at 100°C.  Equal amounts of protein were separated by SDS-
PAGE (10% resolving gel), transferred to a nitrocellulose membrane and probed with either 
an anti-adiponectin rabbit polyclonal antibody (1:750) (Alpha Diagnostics, San Antonio, 
TX), anti-Ser473 PKB rabbit polyclonal antibody (1:2000) (Cell Signaling Technology, 
Danvers, MA), anti-PKB (1:1000) (Cell Signaling Technology), or  anti-AMPK (1:1000) 
(Cell Signaling Technology) overnight at 4°C.  Both the total and phospho-specific PKB 
antibodies detect all isoforms. The porcine adiponectin antibody was generated against the 
following two peptides: DQYQDKNVDQASGS and TEKPGALLPVPKGAC.  Anti-
adiponectin was purified from immunized rabbit serum by affinity chromatography.  
Membranes were then probed with a goat anti-rabbit IgG horseradish peroxidase (1:10,000) 
(Pierce) for 1 hour at room temperature.   Blots were developed using the SuperSignal West 
Pico Chemiluminescent Substrate system (Pierce) and imaged with FOTO/Analyst Luminary 
FX system (Fotodyne Incorporated, Hartland, WI).  Densitometry was performed using 
TotalLab TL100 software (TotalLab Ltd, Newcastle, UK).  Serum (2 L) was diluted in 
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reducing loading buffer, heat denatured, and separated by SDS-PAGE as described above for 
estimation of serum adiponectin concentrations.  Phosphorylation of AMPK at Thr172 was 
measured by ELISA (Cell Signaling Technology). 
Statistical Analysis.  All statistical procedures outlined were performed using SAS 9.2 
(SAS, Cary, NC).  Residuals were analyzed to detect outliers and assess normality using the 
PROC Univariate procedure.  Right-skewed data were log-transformed for further analysis. 
ANOVA was performed using the PROC GLM procedure.  Main effects included diet and 
tissue where appropriate.  Fixed effects include sex, group, and termination date.  Fixed 
effects were used in the model when p≤0.15 for the fixed effect or interaction with main 
effect(s).  Blood glucose data from the insulin challenge were analyzed using an 
autoregression order of one repeated measures.  For flow cytometry data analysis was 
weighted on live cell number.  Additionally, %CD203a
+
 was used as a covariate for analysis 
of CD14 and CD16 data.  Data presented are least-squares means ± standard error. 
Results 
Dietary fatty acid profiles are presented in Table 3.  Only the LFC and HFPn3 diet 
contained measurable EPA and DHA while all three diets contained -linolenic acid.  The 
addition of n-3 PUFA to the HFPn3 diet decreased the n-6:n-3 from 47.6 in the HFP diet to 
3.9 in the HFPn3 diet.  The average calculated n-3 PUFA consumption was 0.40, 0, and 7.6 
g/d for EPA, and 0.36, 0, and 6.7 g/d for DHA for the LFC, HFP, and HFPn3 groups, 
respectively.  To maintain lean mature body weight, caloric intake was limited in the LFC 
group to an average of 1778 kcal/d compared to ~9800 kcal/day for the two high fat diets.  
Final body weights for the two high fat groups did not differ (Table 4).  
70 
 
To assess the impact of the high fat diet and n-3 supplementation on systemic 
metabolic disturbances, insulin, blood glucose, cholesterol, triglycerides, homocysteine, and 
blood pressure were measured (Table 4).  There was no difference detected among the LFC, 
HFP, and HFPn3 groups in fasting serum insulin, cholesterol, triglyceride, or homocysteine 
concentrations.  In contrast, there was a dietary effect with serum NEFA; the HFPn3 group 
had higher NEFA concentrations than the LFC group, whereas the HFP group was not 
different from either the LFC or the HFPn3 group.  Additionally, consumption of either high 
fat diet increased systolic blood pressure, diastolic blood pressure, and mean arterial 
pressure.  Although there were no differences in serum insulin concentrations, the LFC group 
had lower fasting blood glucose than either the HFP or HFPn3 groups.  The high fasting 
blood glucose concentrations of pigs fed the HFP or HFPn3 diets caused an increase in 
HOMA-IR as compared with the LFC group.   
Also summarized in Table 4, there were no differences in serum CRP or TNF 
attributable to dietary treatment.  However, serum CRP was positively correlated with fasting 
blood glucose (r=0.42716, p=0.0421).  IL-6, IL-10, and IL-12 were detectable in the serum 
of only two pigs (data not shown).  Serum adiponectin was decreased by both high fat diets 
vs. the control group, but the magnitude of this decrease was attenuated in pigs fed the 
HFPn3 diet (Figure 1A).  Serum adiponectin was negatively correlated with fasting blood 
glucose (r=-0.44268, p=0.0287).   
To assess whether differences in serum adiponectin were associated with altered 
AMPK activity, we measured LD muscle AMPK phosphorylation.  Both the HFP and 
HFPn3 groups had decreased phosphorylation of AMPK at Thr172, and a decreased ratio of 
Thr172 AMPKto total AMPK as compared with the LFC group, but did not differ in total 
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AMPK (Figure 1B-D).  Phosphorylation of AMPKat Thr172 was positively correlated 
with serum adiponectin concentration (r=0.47112, p=0.0233) and negatively correlated with 
fasting blood glucose (r=-0.49803, p=0.0156).  Additionally, we determined whether there 
was a dietary influence on ectopic lipid deposition.  Percent lipid in liver and LD muscle was 
not influenced by diet (Table 3).   
Insulin sensitivity was assessed by measuring the decrease in blood glucose following 
an insulin challenge.  Blood glucose was decreased by 5 min in the LFC group, and by 10 
min in the group fed the HFPn3 diet (Figure 2).  The HFP group was unresponsive to insulin 
over the 15 min insulin challenge (Figure 2).    Tissue differences in insulin signaling were 
assessed by evaluating phosphorylation of PKB at Ser473.  The HFPn3 diet decreased PKB 
abundance in SQ, VIS, and OM adipose depots (Figure 3A, 3D, 3G).  However, there was 
no difference is Ser473 phosphorylation of PKB (Figure 3B, 3E, 3H).  The ratio of Ser473 
PKB to total PKB was decreased in the SQ and OM depots by the HFP diet, but not the 
HFPn3 diet (Figures 3C, 3I), but was unchanged in the VIS depot (Figure 3F).  There was 
no difference in liver or LD muscle total PKB, or PKB phosphorylation (data not shown). 
Adipose tissue macrophages were evaluated by flow cytometry to determine both the extent 
of macrophage infiltration (CD203a) and phenotype.  Phenotype was determined by the 
presence of CD16, an Fc receptor, and CD14, the co-receptor for tlr4.  The percent of 
macrophages in adipose depot SVC was decreased in the HFP and HFPn3 groups with no 
difference amongst adipose depots (Figure 4A).   
The HFP and HFPn3 groups had increased CD16
+
 macrophages in the adipose tissue 
compared with the LFC group, with no difference among the adipose depots (Figure 4B).  
There was no difference in CD16
+
 CD14
+
 macrophages among dietary treatments; however, 
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the OM adipose depot had decreased CD16
+
 CD14
+
 macrophages compared to the SQ 
adipose depot (Figure 4C).  Additionally, the HFP diet increased the percent CD16
-
 CD14
+
 
macrophages compared with the LFC and HFPn3 groups (Figure 4D) with no differences 
across adipose depots.   
Discussion 
Comparative animal models are critical to understanding the development of human 
obesity and the chronic inflammation in adipose tissue which contributes to the pre-diabetic 
state (i.e., metabolic syndrome).  Although previous studies (11; 24; 33-34) have underscored 
the potential value of the Ossabaw pig as a model for obesity and pre-diabetes, this is to our 
knowledge the first study to address obesity-linked inflammation in adipose tissue of the 
Ossabaw pig, or the potential alleviation of this inflammation by dietary n-3 fatty acids. 
Whereas others (20) have reported increased circulating concentrations of TNF in response 
to diet-induced obesity in Ossabaw swine, we found no diet-related increase in serum 
concentrations of common pro-inflammatory markers, TNF, CRP, IL-6, or  IL-12, despite 
the prolonged duration of our study and the marked development of obesity (i.e., over 100 kg 
weight gained beyond mature body weight).  Whether this difference relates to differences in 
diet composition across studies is currently unresolved.  It is noteworthy that whereas others 
(20) have attributed both inflammation and liver injury to the presence of fructose in 
atherogenic diets, our diet contained sucrose which contributed 14% fructose to the diet on a 
weight basis), and no added cholesterol.  However, it is also intriguing to note that reduced 
ectopic storage of lipid in liver and skeletal muscle due to increased capacity for expansion 
of adipose mass has been associated with improvements in metabolic markers associated 
with obesity (17), and presumably, alleviation of obesity-linked inflammation.  We saw no 
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evidence of ectopic lipid accumulation in the liver or skeletal muscle of pigs fed either high 
fat diet.  Consequently, the marked capacity of the Ossabaw swine used in our study to 
expand adipose mass may in fact afford them some protection against obesity-linked 
inflammation.   
To evaluate adipose inflammation in this model and make comparisons with human 
literature, we investigated the adipose tissue macrophage population in lean vs. obese 
Ossabaw swine.  Several studies of human adipose tissue have categorized macrophages as 
being CD14
+ 
(4; 18; 35; 41).   In our study, only a small percentage (8-10%) of the adipose-
derived SVC were identified as CD14
+
. Consequently, we used the mature macrophage 
marker, CD203a, to identify macrophage populations and the markers CD14 and CD16 to 
assess phenotypic changes associated with diet or adipose depot. Surprisingly, both the HFP 
and HFPn3 groups had fewer macrophages than the LFC group, although this decrease did 
not occur in all depots across diets.  It seems possible that accelerated macrophage turnover 
in obese pigs led to an increase in adipose monocytes not expressing CD203a.  It is also 
possible that recruitment of adipogenic progenitors, due to rapid expansion of adipose mass 
in pigs fed the high fat diets, decreased the overall percentage of macrophages in the SVC 
population.   
The predominant population of adipose macrophages in the Ossabaw pig were 
CD16
+
, with the vast majority of these being CD14
-
.  This is quite intriguing as there is a 
paucity of information relating to this particular phenotype of adipose macrophages.   Given 
that CD16
+
CD14
-
 monocytes are anti-inflammatory (7), it is quite possible that adipose 
inflammation in obese Ossabaw swine may be minimized by the majority of macrophages 
being of the CD16
+
CD14
-
 phenotype.  However, it is important to note that there was in fact 
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an increase in the number of CD16
-
CD14
+
 macrophages detected in the adipose tissue of pigs 
fed the HFP diet vs. the LFC or HFPn3 groups.  In humans, classical CD16
-
CD14
+
 blood 
monocytes express high levels of CCR2 and CD62L (29), and are thus pro-inflammatory (7).  
This perhaps indicates  that the greater number of  CD16
-
CD14
+
 macrophages  in the adipose 
tissue of pigs fed the HFP diet reflects obesity-linked infiltration with pro-inflammatory 
cells, and that the HFPn3 diet protected against this infiltration, despite the marked obesity.  
It is noteworthy, that we have previously demonstrated that dietary supplementation with n-3 
fatty acids causes enrichment of both adipose tissue and muscle (14), and thus higher 
concentrations of n-3 PUFA in the adipose tissue of pigs fed the HFPn3 diet may have 
protected them from the increase in the CD16
-
CD14
+
 macrophages.   
As regards indicators of pre-diabetes, fasting hyperglycemia was readily induced by 
both high fat diets, and this occurred with increased HOMA-IR and blood pressure measures.  
Hyperglycemia and hyperinsulinemia have been reported (19-20) in pig models, although 
insulin peaked at one month and decreased thereafter in one study (19).  The degree of 
hyperglycemia induced by the high fat diets without concomitant hyperinsulinemia is 
striking.  There are instances where hypoinsulinemia is present in a diabetic state (9), and 
may be caused decreased beta cell function due to chronic hyperglycemia (10).  However, 
this has not been addressed in this model to our knowledge.  Although, cholesterol and 
triglycerides have also been increased by high fat diets in several studies utilizing swine (11; 
19-20; 24), the diets used in our study did not cause significant increases in either.   It should 
be noted that we did not add cholesterol to the diets as other researchers have done (11; 20; 
24).   In Ossabaw swine, dietary cholesterol likely plays a pivotal role in the development of 
hypercholesterolemia and hypertriglyceridemia.  Circulating NEFA were increased in only in 
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the HFPn3 group vs. the LFC group.  This is most likely a consequence of the slightly higher 
fat content of the HFPn3 diet due to addition of the n3 fatty acid source. 
In the context of obesity, the activity of AMP-activated protein kinase (AMPK) is 
quite important due to its stimulation of glucose uptake and fatty acid oxidation in muscle 
(31; 40).  Relative to the control group, we found that both obese groups had decreased 
abundance of phosphorylated Thr172 AMPK and a decrease in the ratio of phosphoThr172 
AMPK to total AMPK in the LD muscle.  Genetically, Ossabaw swine contain the 
mutation Val199→Ile in the PRKAG3 (the 3 isoform of AMPK) gene which negatively 
affects the activity of AMPK (22).  It   has been hypothesized that decreased AMPK activity 
due to this mutation  is causal in the development of insulin resistance in Ossabaw pigs  (27).  
Although adiponectin clearly stimulates activation of AMPK (40), it seems unlikely that the 
relatively small decrease in serum adiponectin in the obese groups vs. the control group 
contributed to the reduction in Thr172 AMPK.  Given the PRKAG3 mutation, it will indeed 
be intriguing to determine whether Ossabaw pigs are more susceptible to the effects of high 
fat diets on AMPK activity than are pigs of commercial lean lines. 
Changes in blood glucose concentrations during the insulin challenge indicated that 
n-3 fatty acid supplementation improved insulin sensitivity vs. pigs fed the HFP diet.  
However, there was no dietary difference in Ser473 PKB in adipose tissue, liver, or LD 
muscle after insulin stimulation.  Total PKB was decreased in all adipose depots compared to 
the LFC group and Ser473 PKB:PKB was increased in SQ and OM adipose depots in pigs fed 
the HFPn3 diet compared to the HFP pigs.  In adipocytes, activation of peroxisome 
proliferator-activated receptor (PPAR) by thiazolidinediones decreases PKB abundance 
specifically (38).  Previous work has shown that n3 fatty acids (or their metabolites) are 
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ligand activators of PPAR(3; 25) and it is quite possible that the reduction in PKB reflects 
this activity of n-3 fatty acids in adipocytes.  Nonetheless, the reduction in PKB did not 
preclude the stimulation of glucose uptake by insulin during the insulin challenge.  
Additionally, it should be noted that the insulin challenge was performed under anesthesia, 
which although necessary for this study, is also limitation. 
In summary, we have shown marked obesity, hyperglycemia, hypertension and a 
modest reduction in circulating adiponectin concentrations in Ossabaw swine fed a diet high 
in saturated fat.  However, there were only limited indications of the expected obesity-linked 
inflammation in adipose tissue. The predominate evidence of inflammation was the increased 
CD16
-
CD14
+ 
macrophages in the adipose tissue of the HFP group, which are most likely pro-
inflammatory macrophages.  Despite the lack of a clear inflammatory response, the HFP 
group had decreased sensitivity to administration of exogenous insulin as compared with the 
control and HFPn3 groups.  Major effects of n-3 fatty acid supplementation were determined 
to be the regulation of PKB abundance, improved insulin-stimulated glucose clearance 
during the insulin challenge, and blunted infiltration of adipose tissue with CD16
-
CD14
+
 
macrophages.   Further investigation with the monocytic markers CD172a and CD163 may 
provide further insight to adipose depot macrophage populations in this novel model of 
obesity and pre-diabetes.   Finally, the loss of three pigs from the HFPn3 dietary treatment, 
although not definitively linked to diet, limited our statistical power in studying the beneficial 
effects of n-3 PUFA in this model.  
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Tables 
 
Table 2. Ingredient composition of the diet (%) as-fed. 
Ingredient Diet 
 LFC HFP HFPn3 
Corn 46.92 25.06 13.32 
Soybean Meal-48 4.00 19.55 21.35 
Sucrose - 28.00 28.00 
Palm Oil - 18.00 18.00 
Menhaden Meal 7.50 - - 
Soybean Hulls 33.44 - - 
Wheat Bran 3.00 - - 
Canola Oil 1.00 - 3.00 
Gromega
TM
 365
1
 1.00 - 5.00 
Meat & Bone Meal
2
 - 6.25 6.25 
Vitamin Mix 0.50 0.50 0.50 
Salt 0.40 0.40 0.40 
Mineral Mix 0.10 0.10 0.10 
Selenium Mix 0.05 0.05 0.05 
DL-Methionine - 0.07 0.09 
Dicalcium Phosphate 1.88 1.63 1.64 
Limestone 0.21 0.38 2.30 
Ethoxyquin
3
 0.0125 0.0125 0.0125 
Metabolizable Energy (kcal/kg) 2750 4059 4058 
Fat (kcal/kg) 382 1572 1877 
Ether Extract (%) 4.69 20.27 23.98 
Crude Protein (%) 14.92 15.14 15.00 
Lysine (%) 0.81 0.80 0.83 
Methionine (%) 0.29 0.29 0.29 
Met + Cys (%) 0.47 0.50 0.50 
Crude Fiber (%) 13.69 1.39 1.19 
Calcium (%) 0.90 1.20 1.93 
Available Phosphorous 0.60 0.60 0.60 
1
JBS United, Sheridan, IN; 
2
Darling International, Des Moines, IA; 
3
Novus International, St.  
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Table 3. Dietary fatty acid profile (g/100 g total fatty acid). 
Fatty Acid Diet 
 LFC HFP HFPn3 
6:0 0.00 0.00 0.00 
8:0 0.00 0.00 0.00 
10:0 0.66 0.80 0.75 
12:0 0.00 1.44 2.12 
14:0 2.34 1.06 1.59 
14:1 0.00 0.00 0.00 
16:0 18.47 43.98 38.85 
16:1 2.51 0.00 0.89 
18:0 4.08 5.18 4.83 
18:1 28.14 36.6 37.58 
18:2n6 34.14 10.73 10.49 
18:3n6 0.00 0.00 0.00 
18:3n3 3.77 0.23 1.03 
20:0 0.44 0.00 0.21 
20:1 0.66 0.00 0.00 
20:2 0.00 0.00 0.00 
20:3 0.00 0.00 0.00 
20:3n6 0.00 0.00 0.00 
20:4n6 0.00 0.00 0.00 
20:5n3 2.33 0.00 0.88 
22:1 0.00 0.00 0.00 
22:2 0.00 0.00 0.00 
24:0 0.00 0.00 0.00 
22:6n3 2.10 0.00 0.78 
Other 0.37 0.00 0.00 
Total 100.00 100.00 100.00 
Saturated 26.36 52.45 48.35 
n3 8.20 0.23 2.69 
n6 34.14 10.73 10.49 
n6/n3 4.16 47.59 3.91 
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Table 4. Growth and metabolic parameters of Ossabaw swine at termination. 
Parameter Diet p-value 
 LFC HFP HFPn3  
Final Body Weight (kg) 49.6±4.7
a
 156.7±5.3
b
 154.4±5.8
b
 <0.0001 
Insulin (pg/mL) 63.5±8.6 80.3±11.7 76.5±14.7 0.44 
Blood Glucose (mg/dL) 119.8±14.8
a
 233.5±29.4
b
 221.5±34.4
b
 0.0011 
HOMA-IR 0.44±0.12
a
 1.03±0.13
b
 0.97±0.18
b
 0.0121 
Cholesterol (mg/dL) 68.4±5.7 90.8±6.4 79.0±6.9 0.06 
Triglycerides (mg/dL) 42.0±7.1 61.9±7.4 61.4±8.7 0.11 
Liver Lipid (%) 4.23±0.18 4.54±0.18 4.58±0.22 0.39 
LD Lipid (%) 3.53±1.06 5.90±1.10 5.98±1.29 0.21 
NEFA (mM) 0.57±0.22
a
 1.13±0.23
ab
 1.46±0.27
b
 0.0453 
CRP (ng/mL) 13.7±2.5 20.6±2.6 18.4±3.0 0.17 
TNF (pg/mL) 24.9±3.2 21.6±2.8 15.5±2.3 0.10 
Homocysteine (M) 11.5±5.8 33.0±5.2 26.2±8.1 0.06 
Diastolic BP 63.4±7.9
a
 96.3±7.1
b
 102.0±9.0
b
 0.0251 
Systolic BP 127.2±6.9
a
 170.1±6.3
b
 178.7±8.1
b
 0.0021 
Mean Arterial Pressure 93.6±8.9
a
 118.0±7.9
b
 134.0±10.2
b
 0.0275 
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Figures 
 
Figure 1. n-3 fatty acids attenuate the high palm oil induced decrease in serum adiponectin, 
but do not alter AMPK. 
 
(A) Relative serum adiponectin and (B) AMPK, (C) Thr172 AMPK, and (D) Thr172 
AMPK:AMPK of LD Ossabaw swine fed low fat control (LFC), high fat palm oil (HFP), 
or high fat palm oil plus n-3 fatty acids (HFPn3) diets.  Values are (A-B) arbitrary 
densitometric units or (C) arbitrary units per mg protein..  Means with different letters 
represent a difference of p<0.05.  Main effects (A) Diet p=0.0410; (B) Diet p=0.42; (C) 
Diet=0.0055; (D) Diet p=0.0136. 
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Figure 2. n-3 fatty acids attenuate high palm oil induced insulin resistance. 
 
Blood glucose from Ossabaw swine challenged with 0.25 IU/kg porcine insulin after a 12 
hour fast from 3 dietary treatments: low fat control (LFC), high fat palm oil (HFP), high fat 
palm oil plus n-3 fatty acids (HFPn3). Differences are from 0 to 5 min, 5 to 10 min, and 10 to 
15 min within diet are represented by *, †, and ‡, respectively.  Main effects: Diet p=0.0004, 
Time p=<0.0001, Diet*Time p=0.0481. 
  
86 
 
 
Figure 3. Insulin resistance is not reflected in adipose tissue S473 PKB phosphorylation. 
 
(A) PKB, (B) Ser473 PKB, and (C) Ser473 PKB:PKB of subcutaneous adipose (SQ),  (D) 
PKB, (E) Ser473 PKB, and (F) Ser473 PKB:PKB of visceral adipose (VIS), and (G) PKB, (H) 
Ser473 PKB, and (I) Ser473 PKB:PKB of omental adipose (OM) from Ossabaw swine fed low 
fat control (LFC), high fat palm oil (HFP), or high fat palm oil plus n-3 fatty acids (HFPn3) 
diets.  Values are arbitrary densitometric units.  Means with different letters represent 
difference of p<0.05.  Main effects: (A) Diet p=0.0238; (B) Diet=0.34; (C) Diet p=0.0141; 
(D) Diet p=0.0326; (E) Diet=0.18; (F) Diet p=0.22; (G) Diet p=0.0153; (H) Diet=0.12; (I) 
Diet p=0.0032. 
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Figure 4.  High fat diets have fewer macrophages, but phenotype is altered by obesity and 
depot. 
 
(A) Macrophages (CD203a), and (B) CD16
+
 macrophages by diet, (C)  CD16+CD14
+
 
macrophages by adipose depot, and (D) CD16
-
 CD14
+ 
macrophages by diet in subcutaneous 
(SQ), visceral (VIS), and omental (OM) adipose depots from Ossabaw swine fed low fat 
control (LFC), high fat palm oil (HFP), or high fat palm oil plus n-3 fatty acids (HFPn3) 
diets.  Values are percent positive out of SVC’s.  Means with different letters represent 
difference of p<0.05.  Main effects: (A) Diet p=0.0002, Tissue p=0.9192, Diet*Tissue 
p=0.0007; (B) Diet p=p<0.0001, Tissue p=0.10, Diet*Tissue p=0.21; (C) Diet p=0.50, Tissue 
p<0.0443, Diet*Tissue p=0.98; (D) Diet p=0.0053, Tissue p=0.65, Diet*Tissue p=0.74. 
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CHAPTER 4: ADIPOGENIC POTENTIAL OF OSSABAW ADIPOCYTES 
PROTECTS AGAINST IL-8 SECRETION 
 
Abstract  
Some obese individuals appear to be protected against obesity-linked adipose tissue 
inflammation and the ensuing metabolic consequences.  This protection may be afforded by 
an inherent ability to markedly expand adipose tissue by hyperplasia in response to excess 
caloric intake, as it has been previously demonstrated that adipose tissue expansion improves 
both the metabolic and inflammatory profile.  It was determined that Ossabaw swine develop 
minimal evidence of inflammation, despite morbid obesity induced by long-term 
consumption of a high fat diet.  The ability of Ossabaw swine to store large amounts of lipid 
in adipose tissue when provided excess calories may have provided protection against the 
development of inflammation.  Thus, we hypothesized that Ossabaw adipocytes will have 
increased adipogenesis and be protected against palmitate-induced inflammation and insulin 
resistance compared with Yorkshire adipocytes.  Ossabaw adipocytes have increased clonal 
expansion, PPAR expression, and G3PDH activity compared to Yorkshire adipocytes.  
Palmitate activated NFB, but activation was not different between Ossabaw and Yorkshire 
adipocytes.   However, palmitate only induced IL-8 production in Yorkshire adipocytes.  The 
increased adipogenic potential of Ossabaw adipocytes may be protective against palmitate 
induced IL-8 production.  This is confirmed by the lack of obesity-linked increases in serum 
and adipose tissue IL-8 concentrations in Ossabaw swine.  As determined by 2-NBDG 
uptake, insulin sensitivity was decreased by both palmitate, irrespective of genotype.  
However, Ossabaw adipocytes had both lower basal and insulin-stimulated 2-NBDG uptake.  
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Thus, the in vitro evidence supports that the adipogenic potential of Ossabaw adipocytes may 
be protective against palmitate induced inflammation with respect to IL-8 production. 
Introduction 
 The prevalence of obesity is increasing in the United States (16).  Obesity is 
considered a state of chronic low-grade inflammation.  Nearly all of the co-morbidities 
associated with obesity can be linked to inflammation (3; 29).  It is estimated that ~80% of 
individuals with type 2 diabetes (31) and 65% of individuals with the metabolic syndrome 
(15) are obese.  Some obese individuals appear to be protected against obesity-linked 
inflammation and metabolic disturbances (22; 38).  These individuals are termed 
metabolically healthy but obese (MHO).  MHO individuals have decreased inflammation 
compared to their un-healthy counterparts, including lower C-reactive protein (CRP) (21; 
37), interleukin 6 (IL-6) (24; 37), and tumor necrosis factor (TNF)  (24) as well as 
increased adiponectin (1; 44).   
 In addition to decreased inflammation, MHO individual have a more favorable 
metabolic profile.  Compared with their un-healthy obese counterparts, MHO individuals 
have less visceral fat (7; 18; 20-21; 24; 44) and less ectopic lipid deposition in muscle (39; 
44) and liver (39), despite similar BMI (7; 18; 20-21; 37) and body fat percentage (7; 21).  
Additionally, MHO individuals have decreased circulating concentrations of triglycerides (7; 
18; 20-21; 24; 37), total cholesterol (24), LDL-cholesterol (24; 37), and increased 
concentrations of HDL-cholesterol (7; 21; 24; 37) compared to their un-healthy counterparts.  
MHO individuals retain insulin sensitivity (7; 18; 20-21; 37; 39) and have lower fasting 
insulin (7; 20-21) and glucose (7; 18; 20). 
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 An extraordinary ability to expand subcutaneous adipose tissue may be a fundamental 
component of the favorable metabolic profile exhibited by MHO individuals.  Evidence 
suggests that adipose tissue has a genetic limit on its ability to expand by hypertrophy and 
hyperplasia; and that the ability to expand varies by depot (12).   Excess energy intake may 
exhaust the body’s ability to store fat in adipose tissue, leading to ectopic lipid deposition in 
the muscle and liver.  Ectopic lipid deposition has been closely linked to the development of 
insulin resistance (45).  In ob/ob mice (devoid of leptin), the induction of adipose tissue 
expansion by over-expression of adiponectin attenuates insulin resistance and improves 
systemic inflammation normally seen in this model, despite morbid obesity (23).   
Swine are increasingly being used as a biomedical model for researching obesity, 
insulin resistance, and cardiovascular disease (8; 10; 26-27; 30; 35).  Ossabaw swine are an 
interesting model for studying obesity and its co-morbidities due to the breed’s ability to 
accumulate lipid, develop impaired glucose tolerance, and frequent development of insulin 
resistance (28; 30; 42-43).  However, we recently found that when fed a high fat diet for 30 
weeks, Ossabaw swine display little evidence of the expected chronic low-grade 
inflammation associated with morbid obesity (14).  Potentially, the ability of Ossabaw swine 
to accumulate adipose tissue may protect them against the development of inflammation.  
Thus, we hypothesized that the ability of Ossabaw swine to expand adipose tissue more 
readily than lean commercial swine will be evident by increased adipogenesis in Ossabaw 
stromal vascular cell (SVC) derived adipocytes and that they will have decreased palmitate-
induced inflammation and insulin resistance compared to Yorkshire SVC derived adipocytes. 
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Methods 
Animals.  All animal procedures were conducted at Iowa State University and were 
approved by the Iowa State University Institutional Animal Care and Use Committee.  To 
demonstrate the ability of Ossabaw swine to expand adipose tissue, subcutaneous (SQ) and 
visceral (VIS) adipose tissue was collected from a study previously described (14).  Briefly, 
27 mature male and female Ossabaw swine were fed three diets for 30 weeks: a restricted 
Low Fat Control (LFC), an ad libitum High Fat Palm Oil (HFP), and an ad libitum High Fat 
Palm Oil plus n-3 fatty acids (HFPn3).  Final body weights for the three diets were 49.6, 
156.7 and 154.4 kg, respectively.  Additionally, SQ adipose tissue was collected from 
Yorkshire swine (~110 kg) to compare adipocyte size. 
Adipocyte Size. Frozen sections of adipose depots were placed in 10% neutral 
buffered formalin overnight and then embedded in paraffin.  Thereafter, sections of 5 µm 
thickness were mounted onto microscope slides for staining with hematoxylin and eosin for 
analysis of adipocyte area and adipocyte number.  Slides were imaged with a LEICA DM1 
3000B microscope (LEICA Microsystems Inc., Buffalo Grove, IL) equipped with a QICAM 
Fast 1394 camera (QIMAGING, Surrey, BC, Canada).  Adipocyte area was analyzed from an 
average of 6 fields at 10X magnification with AxioVision LE 4.8.2 (Carl Zeiss AG, 
Thornwood, NY).  Measurements were taken from duplicate slides. 
Cell Culture.  SVC were isolated from lean Ossabaw and Yorkshire swine as 
previously described (14).  Cells were grown in LG-DMEM (pH 7.4) supplemented with 
10% FBS, 100 U/mL penicillin, 100 g/mL Streptomycin, 5 g/mL gentamicin, and 2.5 
g/mL Amphotericin B.  Media was changed every two days during the growth phase until 
one day after confluency.  For differentiation of SVC into adipocytes, growth media was 
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supplemented with 100 nM insulin, 0.1% ITS (Sigma-Aldrich, St. Louis, MO), 0.5 mM 3-
isobutyl-1-methylxanthine, 1 M dexamethasone, 33 M biotin, 17 M pantothenic acid, 
and 5 M troglitazone for 6 days.  Thereafter, the media was changed at days 6 and 8 to 
growth media supplemented with 100 nM insulin 0.25 M dexamethasone, 33 M biotin, 
and 17 M pantothenic acid. All experiments utilized SVC between passages 3 and 6.   
SVC Proliferation and Differentiation.  SVC growth phase proliferation was 
determined for 3 days using BrDU incorporation (Millipore, Billerica, MA).  Additionally, 
clonal expansion was measured for the first 3 days of differentiation using BrDU 
incorporation (Millipore).  At days 10 days post-differentiation, adipocytes were stained with 
Oil Red O as follows: Cells were fixed for one hour with 10% neutral buffered formalin.  
Then were washed 3X with 60% isopropanol and stained for 10 minutes in a 0.21% w/v Oil 
Red-O in 60% isopropanol.  Cells were then washed 4X with tap water and covered with 
50% glycerol.  Images were taken as described above for quantification of lipid droplet size.  
Cells were then washed 4X with tap water and air dried.  Oil Red O was extracted with 100% 
isopropanol for 30 minutes with rocking and was quantified by measuring the absorbance at 
500 nm. 
G3PDH.  The enzyme activity of glycerol-3-phosphate dehydrogenase (G3PDH) was 
determined from 10 day post-differentiation Ossabaw and Yorkshire SVC cell lysate.  The 
assay for G3PDH was performed as described by Gamou et al. (17).  Briefly, cell lysate was 
added to 100 L of reaction buffer (125 mM Triethanolamine-HCl pH 7.5, 2.5 mM EDTA, 
0.5 mM NADH, 1.1 mM dihydroxyacetone phosphate, 0.125 mM -mercaptoethanol) and 
the absorbance was read at 340 nm.  Reagents for G3PDH activity were obtained from 
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Sigma-Aldrich (St. Louis, MO).  Absorbance measurements were taken at 340 nm every 30 s 
for 7 min at 25°C on Synergy 4 microplate reader (Bio-Tek, Winooski, VT).  G3PDH 
activity was calculated from the change in absorbance at 340 nm and expressed as nmol 
NAD(P)H per min per mg protein. 
Insulin Sensitivity. Ossabaw and Yorkshire adipocytes (10 day post differentiation) 
were treated with Vehicle (untreated), 0.5 mM sodium palmitate, or 10 g/mL LPS 
(Escherichia coli serotype O55:B55) in LG-DMEM (pH 7.4) with 0.1 mM BSA, 100 U/mL 
penicillin, 100 g/mL Streptomycin for 48 hours with a media change at 24 hours.  At 48 
hours, cells were washed once with PBS, and then incubated with or without 100 nM insulin 
for 15 minutes.  Thereafter 2-NBDG (2-deoxy-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-
glucose) (Cayman Chemical, Ann Arbor, MI) was added at a final concentration of 100 
g/mL and incubated for 30 minutes.  Cells were washed twice with PBS and the uptake of 
2-NBDG was measured by fluorescence with the excitation/emission at 485/535 nm.  
Cellular protein was collected and protein was measured using the BCA reagent (Pierce, 
Rockford, IL).  Total cellular protein was used as a covariate for 2-NBDG uptake.  
Western Blot Analysis. Western blots were performed as previously described (14) 
with protein isolated from palmitate and LPS treated adipocytes. Nitrocellulose membranes 
were probed with PPAR rabbit polyclonal antibody (Millipore). 
ELISA. Nuclear Factor  B p 65 nuclear translocation was measured on palmitate and 
LPS treated cells using an ELISA (Cayman Chemical).  Nuclear Extracts were extracted 
according to Cayman Chemical protocol with modifications.  Protease and phosphatase 
inhibitors used in the extractions were 2 mM Na3VO4, 2 mM phenylmethylsulfonyl fluoride, 
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5 g/mL aprotinin, 5 g/mL leupeptin, 5 g/mL pepstatin for both the hypotonic buffer and 
the nuclear extraction buffer.  Media IL-8 and IL-6 were measured on 48 hour cell culture 
treatment media (R&D Systems, Minneapolis, MN).  Additionally, IL-8 concentration was 
determined on serum and SQ and VIS adipose tissue lysate from lean and obese Ossabaw 
swine. 
Myeloperoxidase Activity. Myeloperoxidase activity was determined in serum using 
previously described methods (25; 40) with modifications.  Adipose tissue was homogenized 
in 50 mM potassium phosphate buffer (pH 6.0) with 0.5% (w/v) 
hexadecyltrimethylammonium bromide and freeze thawed and vortexed three times.  
Samples were then centrifuged for 10 minutes at 10,000 x g and the supernatants were 
collected.  Adipose tissue supernantants and serum were mixed with o-dianasidine 
dihydrochloride and 0.005% (v/v) hydrogen peroxide.  The oxidation of o-dianasidine was 
measured by the change of absorbance over a 10 minute period at 460 nm and 25°C.  One 
unit of myeloperoxidase activity was defined as that degrading one mol of hydrogen 
peroxide per min at 25°C.  A molar extinction coefficient of 1.3 x 10
4
 M
-1
 cm
-1
 was used for 
determining myeloperoxidase activity. 
Statistical Analysis. All statistical procedures outlined were performed using SAS 9.2 
(SAS, Cary, NC).  Residuals were analyzed to detect outliers and normality using the PROC 
Univariate procedure.  Right-skewed data were log-transformed for further analysis. 
ANOVA was performed using the PROC MIXED procedure.  Main effects for Ossabaw 
tissue data included lean (LFC) and obese (HFP and HFPn3) and tissue where appropriate.  
Fixed effects include sex, group, and termination date.  Fixed effects were used in the model 
when p≤0.15 for the fixed effect or interaction with main effect(s).  Cell culture data for 
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Western and NFB ELISA analysis were done with a cell culture lot containing an even 
mixture of SVC from 3 pigs from the respective breed.  All other data was done on three 
separate SVC from each breed unless otherwise noted.  SVC replicate was included in the 
model when p≤0.15 for the fixed effect or interaction with swine breed.  Data presented are 
least-squares means ± standard error.  Data was considered statistically different when 
p<0.05.     
Results 
 To assess the ability of Ossabaw swine to accrue adipose tissue, we measured 
adipocyte size in SQ and VIS adipose tissue depots (Figure 5).  Swine fed high fat diets (i.e. 
HFP and HFPn3) had marked enlargement adipocytes compared to the LFC fed swine SQ 
and VIS depots, with no difference between adipose depots.  To verify comparable adipocyte 
size of lean Ossabaw and Yorkshire swine, we also determined adipocyte size in Yorkshire 
SQ adipose tissue.  There was no difference in LFC Ossabaw and Yorkshire SQ adipose 
tissue adipocyte size (data not shown).  Thus, our results demonstrate that Ossabaw swine 
have a marked capacity to store excess energy through adipocyte hypertrophy.  Additionally, 
in a lean state, Ossabaw and Yorkshire swine do not differ in adipocyte size. 
 To compare Ossabaw and Yorkshire adipocytes in vitro, SVC from lean Ossabaw and 
Yorkshire SQ adipose tissue were proliferated and differentiated into adipocytes.  Yorkshire 
SVC cells proliferated faster during cell expansion (Figure 6A).  Thus, to ensure comparable 
cell populations, differentiation was not initiated until one day post cell confluence.  During 
the initial stages of differentiation into adipocytes, Ossabaw SVC had increased clonal 
expansion compared to Yorkshire SVC (Figure 6B); representing an increased capacity for 
adipose expansion due to preadipocyte hyperplasia.  Concomitant with the increased clonal 
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expansion, Ossabaw adipocytes also had increased enzymatic activity of G3PDH (Figure 
6C), a marker of adipogenesis.  Despite increased clonal expansion and G3PDH activity, 
Ossabaw adipocytes had decreased uptake of Oil Red O (Figure 7), and therefore decreased 
lipid filling compared to Yorkshire adipocytes.  In addition to clonal expansion and G3PDH 
activity, PPAR1, but not PPAR2 or total PPAR, was increased in Ossabaw compared to 
Yorkshire adipocytes (Figure 8). 
 A glucose analogue, 2-NBDG, was used to test the effect of palmitate and LPS 
treatments on insulin sensitivity in Ossabaw and Yorkshire adipocytes (Figure 9).  Insulin 
increased 2-NBDG uptake in both Ossabaw and Yorkshire adipocytes.  Yorkshire adipocytes 
had both increased basal and insulin-stimulated 2-NBDG uptake compared to Ossabaw 
adipocytes.  Both palmitate and LPS treatment induced insulin resistance compared vehicle 
treatment.  However, palmitate and LPS did not differentially alter insulin resistance in either 
adipocyte genotype.  In spite of the increased basal and insulin-stimulated 2-NBDG uptake 
displayed by Yorkshire adipocytes, both genotypes had a ~1.5 fold increase in 2-NBDG 
uptake following insulin stimulation. 
 Nuclear translocation of NFB p65 was determined in Ossabaw and Yorkshire 
adipocytes (Figure 10A).  NFB nuclear translocation was increased by palmitate and LPS 
in both adipocyte genotypes.  However, there was no difference in NFB translocation 
between Ossabaw and Yorkshire adipocytes.  Cellular PPAR content was determined by 
western blot (Figure 8).  Total PPAR, PPAR1, and PPAR2 content was not altered by 
treatment (i.e. V, P, L), however as mentioned above, Ossabaw adipocytes had increased 
PPAR1 compared Yorkshire adipocytes. 
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In the media, IL-8 production by adipocytes was differentially regulated by treatment 
(i.e. V, P, L), with Yorkshire adipocytes producing significantly more IL-8 than Ossabaw 
adipocytes (Figure 10B).  Both Ossabaw and Yorkshire adipocytes had increased IL-8 
production in response to LPS, but only Yorkshire adipocytes responded to palmitate with 
increased IL-8 production.  Yorkshire and Ossabaw adipocytes did not differ in IL-6 
excretion, nor did either genotype produce IL-6 in response to palmitate (Figure 10C).  
However, like IL-8 Ossabaw adipocytes produced more IL-6 in response to LPS than 
Yorkshire adipocytes.   
Since palmitate induced IL-8 production in Yorkshire, but not Ossabaw adipocytes, 
we determined whether there was any high fat diet-induced increase in serum or adipose 
tissue IL-8 in Ossabaw swine.  There was no diet-induced increase in serum IL-8 
concentrations (Figure 11A).  Additionally, there were no diet or adipose tissue differences 
in IL-8 concentrations (Figure 11B).  Although there was a significant diet*tissue 
interaction, with obese VIS adipose tissue having the highest IL-8 concentrations, and lean 
VIS adipose tissue have the lowest concentrations.  Since IL-8 is a chemokine that causes 
neutrophil extravasation, we determined myeloperoxidase activity in serum and SQ and VIS 
adipose tissue.  There were no differences between lean and obese pigs in serum 
myeloperoxidase activity (Figure 11C).  Furthermore, myeloperoxidase activity was not 
detected in any adipose tissue depot of any pig. 
Discussion 
 As evidenced by Faris et al. (14) and others (4; 6; 27), Ossabaw swine gain 
considerable weight when fed excess calories.  We have demonstrated that this excessive 
body weight gain leads to a ~4.3 and ~8.0 fold increases in SQ and VIS adipocyte size, 
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respectively.  Adipocyte hypertrophy in obese Ossabaw swine is much greater in magnitude 
compared to the ~2 to 3 fold increase in obese human (36) and rodents (25).  Despite 
apparent obesity and adipocyte hypertrophy in SQ and VIS adipose tissue, Ossabaw swine 
did not display any evidence of systemic inflammation, and only a modest increase in a 
potentially inflammatory adipose tissue macrophage phenotype.   In humans, both 
subcutaneous (19) and visceral (33-34) adipocyte size are positively associated with an un-
healthy metabolic profile including impaired glucose homeostasis and hyperlipidemia.  
However, adipocyte size is not correlated with systemic inflammation measured by 
circulating concentrations of TNF, IL-6, and CRP (19).  In addition to no association of 
inflammation with adipocyte size, MHO individuals have decreased macrophage infiltration 
into adipose tissue (34), which likely provides protection against increased systemic 
inflammation.  Thus, the ability to expand adipose tissue may have protected Ossabaw swine 
from increases in systemic inflammation, adipose tissue macrophage infiltration and 
consequently adipose tissue inflammation. 
 In a lean state, Ossabaw and Yorkshire swine have similar adipocyte size despite 
large differences in mature body weight.  Ossabaw swine have a genetic potential to accrue 
and store large amounts of energy in adipose tissue due to excess caloric intake; however, 
genetic selection of Yorkshire swine for lean mass growth limits the ability of Yorkshire 
swine to store energy in adipose tissue.  Potentially, phenotypical and genetic differences 
between Ossabaw and Yorkshire swine will translate to differences in adipocyte cell culture.  
Despite less lipid filling by Ossabaw SVC derived adipocytes, they have increased 
adipogenesis as evidenced by increased clonal expansion, higher expression of PPAR, and 
higher G3PDH activity compared to Yorkshire SVC derived adipocytes.  Thus, we 
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hypothesized that Ossabaw adipocytes will be protected from palmitate-induced 
inflammation, and therefore insulin resistance, due to their ability to expand adipose tissue in 
vivo. 
 To our knowledge, this is the first study to evaluate the effect of palmitate in regards 
to NFB activation and insulin resistance in porcine SVC derived adipocytes.  Similar to 3T3 
L1 adipocytes (2; 5; 11; 41), palmitate induced activation of NFB in both Ossabaw and 
Yorkshire adipocytes.  In spite of no differences in palmitate-induced NFkB activation 
between Ossabaw and Yorkshire adipocytes, IL-8 production was higher in Yorkshire 
adipocytes.  Consistent with this, there were no obesity-linked increases in serum or adipose 
tissue concentrations of IL-8 in Ossabaw swine.  IL-8 is a chemokine that increases 
neutrophil extravasation into tissue during the initial stages of the immune response, and may 
be involved in the initial stages of adipose tissue inflammation in obesity.   
Neutrophil infiltration into adipose tissue happens in the early stages of high fat 
feeding in mice (13), although they are not detectable after 16 weeks.  There is a paucity of 
information regarding neutrophil infiltration in human adipose tissue in obesity.  Neutrophils 
were not detected in adipose tissue of severely obese women, but there was increased 
circulating myeloperoxidase compared to lean women (32), suggesting that while not 
detected in adipose tissue, neutrophil activation is a component of obesity.  Ossabaw 
adipocytes are protected against palmitate-induced IL-8 production, and thus likely 
neutrophil infiltration into adipose tissue of obese swine.  This is confirmed by the absence of 
myeloperoxidase activity in obese Ossabaw swine.   
 Inflammation due to palmitate can be induced by a number of factors other than 
NFB, including JNK, ERK, and p38 MAPK (2; 11; 41).  The lack of IL-6 production by 
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either Ossabaw or Yorkshire adipocytes in response to palmitate does not preclude the 
involvement of these factors in inducing IL-8 production, as palmitate induces NFB 
activation without subsequent IL-6 production.  Induction of IL-6 by LPS in both Ossabaw 
and Yorkshire adipocytes demonstrate distinct differences in Tlr activation between LPS and 
Palmitate.  Evidence from human adipocyte cell culture suggests that the majority of 
inflammation is from the preadipocyte fraction (9).  Thus, the degree of SVC differentiation 
may be a determining factor in cytokine production. 
 Inflammation has been linked to the development of insulin resistance.  Both 
palmitate and LPS decreased insulin-stimulated 2-NBDG uptake by adipocytes.  Perhaps 
most interesting is the lower basal and insulin-stimulated 2-NBDG uptake by Ossabaw 
adipocytes, suggesting differences in capacity to uptake glucose.   Faris et al. (14) 
demonstrated that lean fasted Ossabaw swine challenged with 0.25 U/kg body weight insulin 
have a blood glucose concentration of 60.2 mg/dL (decrease of 57.6 mg/dL) after 15 minutes, 
while fasted Yorkshire swine challenged with 0.1 U/kg body weight insulin have a blood 
glucose concentration of 32.6 mg/dL (decrease of 46.8) after 15 minutes (Faris, R.J. and 
M.E. Spurlock, unpublished data).  This is a substantial increase in insulin sensitivity in 
Yorkshire swine vs. Ossabaw swine, although differences is lean body mass may affect 
insulin responsiveness.  Nonetheless, this increase in insulin sensitivity is reflected in 
adipocyte cell culture.   
 Taken together, this data demonstrates that Ossabaw adipocytes have increased 
adipogenesis, and that this may be protective against inflammation as Ossabaw adipocytes 
did not produce IL-8 in response to palmitate.  Furthermore, Ossabaw adipocytes have 
decreased 2-NBDG basal vs. insulin stimulated glucose uptake which is reflective of in vivo 
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evidence of insulin sensitivity in Ossabaw and Yorkshire swine.  This in vitro evidence 
supports that the marked capacity for adipose expansion in Ossabaw swine to protect against 
high fat diet-induced inflammation, with respect to IL-8 production, but not NFB activation.  
Additionally, this data is supported by the absence of obesity-linked increases in serum and 
adipose tissue IL-8 concentrations. 
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Figures 
 
 
Figure 5. Comparison of SQ 
and VIS adipocyte size in lean 
and obese Ossabaw  103 
Swine. 
 
(A) Adipocyte area of SQ and 
VIS adipose tissue sections 
from lean (LFC) and obese 
(HFP and HFPn3) Ossabaw 
swineand examples of (B) lean 
and (C) obese Ossabaw swine 
adipose tissue sections. Data 
presented is Least-Square 
Means ± standard error.  Main 
Effects: (A) Diet p<0.0001, 
Tissue P=0.31, Diet*Tissue 
p=0.0315. 
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Figure 6. Ossabaw adipocytes 
have increased clonal 
explansion and G3PDH activity 
compared to Yorkshire 
adipocytes. 
 
(A) BrDU incorporation during 
growth phase and (B) 
differentiation phase of 
Ossabaw and Yorkshire SVC.  
(C) G3PDH activity of Ossabaw 
and Yorkshire adipocytes 10 
days post differentiation.  Data 
presented is Least-Square 
Means ± standard error.  Means 
with different letters represent a 
difference of p<0.05.  Main 
Effects: (A) Genotype 
p<0.0001, Day p<0.0001, 
Genotype*Day p=0.0048; (B) 
Genotype p<0.0001, Day 
p<0.0001, Genotype*Day 
p<0.0001; (C) Genotype 
p=0.0104.  Each experiment 
was replicated three times with 
an n=4 for each experiment. 
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Figure 7. Yorkshire adipocytes 
have more lipid filling than 
Ossabaw adipocytes.  
 
(A) Oil Red O extracted from 
Ossabaw and Yorkshire 
adipocytes 10 days post-
differentiation.  Representative 
(B) Ossabaw and (C) Yorkshire 
Oil Red O images.  Data 
presented is Least-Square Means 
± standard error.  Means with 
different letters represent a 
difference of p<0.05.  Main 
Effect: (A) Genotype p<0.0001. 
Each experiment was replicated 
three times with an n=6 for each 
experiment. 
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Figure 8.  Ossabaw adipocytes express more cellular PPAR1 than Yorkshire adipocytes. 
 
Cellular PPARPPARtotalPPARand representative blot in Ossabaw and Yorkshire 
adipocytes treated with Vehicle, Palmitate, and LPS.  There was no difference by treatment.  
Data presented is Least-Square Means ± standard error for Ossabaw and Yorkshire 
adipocytes.    * Represents differences (p<0.05) between Ossabaw and Yorkshire adipocytes 
Main Effects: (PPAR1) Genotype p=0.0151, Treatment p=0.33, Genotype*Treatment 
p=0.40; (PPAR2) Genotype p=0.13, Treatment p=0.51, Genotype*Treatment p=0.81; 
(PPAR) Genotype p=0.13, Treatment p=0.29, Genotype*Treatment p=0.43.  PPAR assay 
was performed on an evenly mixed SVC lot of three pigs with an n=4.   
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Figure 9.  Ossabaw adipocytes have decreased insulin sensitivity compared to Yorkshire 
adipocytes, but do not respond differently to palmitate or LPS treatment. 
 
Insulin stimulated 2-NBDG uptake in Ossabaw and Yorkshire adipocytes treated with 
Vehicle (V), Palmitate (P), and LPS (L).  Data presented is Least-Square Means ± standard 
error.    Main Effects: Treatment p<0.0001; Genotype p<0.0001, Treatment*Genotype 
p=0.33.  Each experiment was replicated three times with an n=4 for each experiment. 
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Figure 10.  Palmitate and LPS 
differentially regulate 
inflammation in Ossabaw and 
Yorkshire adipocytes. 
 
(A) NFB p65 nuclear 
translocation,(B) media IL-8, and 
(C) media IL-6 in Ossabaw and 
Yorkshire adipocytes treated with 
Vehicle (V), Palmitate (P), and 
LPS (L).  Data presented is Least-
Square Means ± standard error.    
Different letter represent a 
difference of p<0.05.  Main 
Effects: (A) Treatment p<0.0001, 
Genotype p=0.86, 
Treatment*Genotype p=0.35; (B) 
Treatment p<0.0001, Genotype 
p=0.0037, Treatment*Genotype 
p<0.0001; (C) Treatment 
p<0.0001, Genotype p=0.0396, 
Treatment*Genotype p=0.0143.  
(A) NFB assay was performed 
on an evenly mixed SVC lot of 
three pigs with an n=5.  (B) IL-8 
and (C) IL-6 assays were 
replicated 3 times with an n=4 for 
each experiment. 
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Figure 11.  Ossabaw swine do 
not have obesity-linked increases 
in IL-8 or myeloperoxidase 
activity. 
 
(A) Serum IL-8,(B) SQ and VIS 
adipose tissue IL-8 and (C) serum 
myeloperoxidase activity of lean 
and obese Ossabaw swine.  Data 
presented is Least-Square Means 
± standard error.    Different letter 
represent a difference of p<0.05. 
Main Effects: (A) Diet p=0.63; 
(B) Diet p=0.90, Tissue p=0.21, 
Diet*Tissue p=0.0004; (C) Diet 
p=0.65. 
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CHAPTER 5: ADIPOSE TISSUE DEPOT DIFFERENCES IN MICROARRAY 
EXPRESSION IN OSSABAW SWINE 
Abstract 
 Obesity is characterized by the increase in adipose tissue mass which can occur in 
multiple adipose tissue depots.  In particular, visceral adiposity is associated with an 
increased risk for the development of type 2 diabetes and cardiovascular disease.  We 
determined the global gene expression of subcutaneous and visceral adipose tissue by 
Affymetrix microarray analysis under conditions of restricted (n=7) or ad libitum (n=7) feed 
intake for 38 weeks in Ossabaw swine.  No genes were determined to be differentially 
expressed by dietary treatment, however, 1494 were determined to be differentially 
expressed (Q<0.05) between subcutaneous and visceral adipose tissue, of which 777 were 
annotated.  Gene ontology and KEGG Pathway analysis were performed using DAVID.   The 
gene ontology cellular component category extracellular region was determined to be over-
represented with 36 genes by depot.  The over-represented KEGG pathways identified 
included arachidonic acid metabolism and chemokine signaling pathway by depot.  These 
genes and pathways identify distinct differences in subcutaneous and visceral adipose tissue 
that may be important in obesity. 
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Introduction 
 Obesity, by definition, is the increase in adipose tissue mass which can occur in 
multiple anatomically distinct adipose tissue depots (i.e. subcutaneous, retroperitoneal, 
mesenteric, omental, etc.).  In addition to adipose tissue depots, obesity may lead to ectopic 
lipid deposition in other tissues, particularly the liver (11), muscle (36), and pancreas (38).  
Waist circumference, which is reflective of abdominal or visceral adiposity and is a 
component of the metabolic syndrome (1), has been increasing in both men and women in 
the United States (29).  Visceral adiposity increases the risk of development of the metabolic 
syndrome (27; 31), and thus increases the risk for development of type 2 diabetes (16) and 
cardiovascular disease (18; 31).   
 Anatomical location of the adipose tissue depot is a determinant in the functional 
properties of the tissue.  Enzymes involved in fatty acid metabolism are differentially 
regulated between adipose tissue depots.  Visceral adipocytes have increased acyl-Co-A 
synthetase (2) and diacylglycerol acyltransferase (DGAT) (2; 22) activity compared with 
subcutaneous adipocytes in overweight individuals, but DGAT is not increased in obese 
individual’s visceral adipocytes (22).  In addition to increased enzyme activities, visceral 
adipose tissue has increased inflammatory gene expression.  Compared to subcutaneous 
adipose tissue, visceral adipose tissue has increased expression of 12/15 lipoxgenase, 
interleukin (IL) 6 , IL-12 p35, CXCL10 (10) , CCL2 (5), and IL-8 (4).  Additionally, 
macrophage secreted factors increase IL-6 production more in visceral adipocytes than 
subcutaneous adipocytes (35).  The increased inflammatory profile of visceral adipocytes is 
important because it can contribute directly to increased liver production of C-reactive 
protein (CRP) (3), and further the chronic low-grade inflammation associated with obesity. 
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 The need for alternative comparative models to investigate differences in adipose 
depot gene expression under lean and obese conditions is evident.  Murine models have been 
pivotal to investigating the etiology of obesity and the roles of specific genes.  However, 
human and mice differ on a number of factors relating to studying adipose tissue and obesity.  
Specifically, CRP is not highly expressed nor is it an acute phase protein in mice (39), human 
macrophages do not produce nitric oxide (32), and gonadal fat is not a major adipose tissue 
depot in humans.  Swine are a viable alternative due to their comparative physiology and 
anatomy.  Ossabaw swine are particular interest because of their ability to accumulate fat 
mass and their previous use in studying obesity and its co-morbidities (12; 15; 28).  Thus, the 
objective of this research was to determine global gene expression in subcutaneous and 
visceral adipose tissue in lean and obese Ossabaw swine. 
Methods 
Animals.  All animal procedures were conducted at Iowa State University and were 
approved by the Iowa State University Institutional Animal Care and Use Committee.  
Fourteen sexually mature male and female Ossabaw swine (Sus scrofa) (average initial body 
weight 46.7 kg) were housed in individual pens in a temperature controlled environment with 
a 12 hour light cycle.  Swine were obtained from the Comparative Medicine Program at the 
Indiana University School of Medicine and Purdue University from a herd that tested 
negative for Brucella spp. and psuedorabies, and showed no clinical evidence of 
communicable disease upon arrival or during the study.  Swine were fed a diet formulated to 
meet minimum requirements for mature swine (33) for 38 weeks.   Dietary treatments were 
ad libitum feed (n=7; 4 male, 3 female) or restricted feed (n=7, 3 male, 4 female).  After 38 
weeks of dietary treatment, animals were fasted 12 hours before blood collection via jugular 
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venipuncture.  Thereafter, animals were anesthetized with telazol:ketamine:xylazine (1:1:1) 
and then were euthanized by exsanguination.   Subcutaneous (SQ) adipose tissue from back 
fat above the 10
th
 rib and visceral adipose tissue (VIS) surrounding the intestines were 
collected and snap frozen in liquid nitrogen.   
Serum analysis. Cholesterol, glucose, triglycerides, and non-esterified fatty acids 
(NEFA) were analyzed using Chol Slides (Ortho Clinical Diagnostics, Rochester, NY), Glu 
slides (Ortho Clinical Diagnostics), Trig Slides (Ortho Clinical Diagnostics), and NEFA-HR 
(Wako Diagnostics, Richmond, VA), respectively, on a Vitros 5.1 Chemistry Analyzer 
(Ortho Clinical Diagnostics).  Serum insulin concentrations were measured by EIA (ALPCO, 
Salem, NH).  The HOMA-IR was calculated using fasting serum insulin (U/mL) x fasting 
blood glucose (mg/dL) divided by 405 (30).  Serum endotoxin was determined using 
Chromogenic LAL Assay (Lonza, Anaheim, CA). 
RNA Isolation. RNA was isolated from SQ and VIS adipose tissue by Guanidinium 
Thiocyanate-Phenol-Chloroform extraction as previously described (7).  Quality and quantity 
of RNA was analyzed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA).  Microarray analysis was performed at the Iowa State University GeneChip 
Facility (Ames, IA) using Affymetrix  Porcine GeneChip Genome Array according to 
manufacturer’s directions (Affymetrix, Santa Clara, CA). 
Microarray analysis. Transcript levels were normalized to the chip median and log 
transformed. For each probeset, the generalized linear model Yij = μ + B1Ti + εij was fit. In 
each ANOVA, Yij is a the log normalized transcript level for the i
th
 treatment and the j
th
 
replicate, μ is the overall mean expression for the feature and Ti represents the i
th
 treatment 
(Treatment, Depot, Sex, Treatment*Depot, Treatment*Sex, Depot*Sex, 
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Treatment*Depot*Sex). An F test of the effect of treatment for each probeset was conducted 
as the ratio of the mean squares for treatment over the mean squares for error, and the p value 
for the test of the null hypothesis (i.e., mean expression not different among the treatments) 
was calculated. We examined the model for conformation to the assumption of normality of 
the residuals testing the null hypothesis that the residuals for each gene were normally 
distributed using the Shapiro-Wilkes Test.  For each p-value, a Q-value was determined to 
control for FDR.  All analyses were performed in SAS 9.2 (SAS Institute, Cary, NC). If the 
test of the null hypothesis of difference across treatments was rejected, and we had no 
evidence for departure from normality of the residuals, we declared the gene differentially 
expressed across treatments.  Microarray data was annotated with gene title, gene symbol, 
and Entrez gene ID (9) (Hu, Z., J. Reecy, and C. Tuggle. Unpublished data).  DAVID (23-24) 
was used to determine over-represented (EASE Score p<0.05) biological process, cellular 
component, and molecular functional categories using the GO FAT databases.  Additionally, 
over-represented KEGG pathways were also determined. 
Statisical analysis. Statistical procedures for serum analysis was performed using 
SAS 9.2 (SAS, Cary, NC).  Residuals were analyzed to detect outliers and normality using 
the PROC Univariate procedure.  Right-skewed data were log-transformed for further 
analysis. ANOVA was performed using the PROC MIXED procedure.  The main effect was 
dietary treatment.  Sex was considered a fixed effect and was included in the model when 
p≤0.15 for the fixed effect or interaction with dietary treatment.   
Results 
 After 38 weeks of dietary treatment ad libitum fed Ossabaw swine became obese 
weighing an average of 118.8 kg compared to the restricted fed Ossabaw swine weighing an 
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average of 59.8 kg.  At the end of the study, obese Ossabaw swine were metabolically 
healthy (Table 5), with was no differences in circulating serum concentrations of insulin, 
glucose, NEFA, or endotoxin.  Nor was there a difference in HOMA-IR.  Both serum 
cholesterol and triglycerides were increased by dietary treatment, although the increase likely 
was not pathological.    
 To determine the effect of dietary treatment, adipose tissue depot, sex, and their 
interactions, microarray analysis was performed on SQ and VIS adipose tissue.  At total of 
19,540 genes were determined to be expressed and included in further analysis.  Of these, a 
total of 9617 genes were successfully annotated.  After controlling for FDR, only 7 genes by 
sex and 1494 genes by depot were determined differentially expressed (Q<0.05).  Only one 
gene (thymosin beta 4, X linked) out of 7 was annotated for sex effect.  For the depot effect, 
777 out of 1494 differentially expressed genes (Q<0.05) were annotated. At a cutoff of 
Q<0.01, 95 out of 185 genes were annotated.  This data is presented in Table 6, with the 
Affy ID, gene title, Q-value, and fold change.  Of these genes, a total of 38 genes were up-
regulated in VIS adipose tissue, relative to SQ adipose tissue, while 57 were down regulated. 
 To determine over-represented gene categories and pathways, the 777 annotated 
differentially expressed genes (Q<0.05) were analyzed by DAVID using the Entrez Gene ID 
for gene ontology molecular function, cellular component, and biological process categories 
(GOFAT) and the KEGG pathway database. The Entrez Gene IDs for all annotated genes 
were used as the background list.  In all, only one cellular component (extracellular region) 
category and two KEGG pathways (arachidonic acid metabolism and chemokine signaling 
pathway) were determined to be over-represented (EASE Score<0.05) by differently 
expressed genes by depot.  Genes expressed in extracellular region, arachidonic acid 
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metabolism, and chemokine signaling pathway categories are listed in Tables 7-9, 
respectively, and will be discussed further in the next section. 
Discussion 
 Despite the duration of the study and body weight gain by the ad libitum fed Ossabaw 
swine, they did not display a perturbed metabolic profile.  Nor did they have any 
differentially expressed genes by dietary treatment after controlling for FDR.  Dietary factors 
may be casual to the development of an un-healthy metabolic profile, and the absence of high 
dietary fat may have precluded the development of altered glucose homeostasis, 
hyperlipidemia, and altered adipose tissue gene expression.  As evidenced by others (12; 28), 
the inclusion of high dietary fat and supra-physiological levels of cholesterol induces 
hyperlipidemia in Ossabaw swine.  Additionally, high dietary fat in itself is enough to induce 
insulin resistance in Ossabaw swine (15).  Nonetheless, distinct differences between SQ and 
VIS depots were evident by microarray analysis. 
 The gene ontology cellular component extracellular region refers to gene products 
that are secreted outside the cell.  Thirty-six genes were over-represented in this category 
(Table 7) from the significant differentially expressed genes by depot.  Four of these genes 
are involved in the insulin-like growth factor (IGF) axis: IGF1, IGFBP3, IGFBP5, and 
IGFBP6.  There is a relative paucity of information relating to IGF-1 and its binding protein 
in regards to different adipose tissue depots.   IGF-1 is important in both the proliferation of 
preadipocytes and differentiation into adipocytes (20; 37).  However, IGF-1-induced PKB 
signaling is impaired in visceral adipocytes compared to subcutaneous adipocytes (8).  IGF-1 
and IGFBP-3 are decreased in response to increased body fat, especially in women (19).  
Additionally, increasing IGF-1 concentrations via growth hormone supplementation 
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decreases visceral adiposity (17; 21; 34).  Whether this is because of increasing IGF-1 or 
directly to growth hormone is unclear.  Potentially, lower concentrations of IGF-1 and 
IGFBP in visceral adipose tissue result in decreased proliferation and cell survival and thus, 
contribute to adipose tissue dysfunction.    
 In addition to IGF proteins, three chemokines were also identified as over-represented 
genes in the extracellular region gene ontology cellular component category (Table 7).  
These chemokines are CCL2, CXCL2, and CCL21.  CCL2 and CXCL2 were down-regulated 
in visceral adipose tissue compared to subcutaneous whereas CCL21 was up-regulated.  
Chemokine signaling pathway was also indentified as a KEGG pathway containing over-
represented genes (Table 9), including CCL2, CXCL2, CCL21, and CCR3.  CCL2 is 
increased in obesity (5), and its importance in macrophage infiltration into adipose tissue is 
well established (26).  In humans, CCL2 is produced at a higher rate in visceral than 
subcutaneous adipose tissue, however, after adjusting for tissue macrophages this difference 
disappeared (5).  Based upon the lack of metabolic and microarray differences by dietary 
treatment, it is likely that the decreased CCL2 expression in visceral adipose tissue is due to 
lack of pathological consequences from diet induced obesity and only reflects strictly depot 
differences.  Other than increased expression of CCR3 in subcutaneous adipose tissue in 
obesity (25), literature pertaining to CCR3, CXCL2, and CCL21 pertaining to obesity and 
adipose tissue depots is absent. 
 In addition to chemokine signaling pathway, seven genes were identified in the 
arachidonic acid metabolism KEGG Pathway as containing over-represented genes by depot 
in our microarray analysis (Table 8).  Products of arachidonic acid metabolism by 12/15 
lipoxygenase induce inflammation and insulin resistance in 3T3 L1 adipocytes (6).  Like 
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humans, our data demonstrates that arachidonate 12/15 lipoxygenase is more highly 
expressed in visceral than subcutaneous adipose tissue (10).  Literature relating to obesity 
and adipose tissue is limited for the other gene indicated in arachidonic acid metabolism 
KEGG pathway.  One gene, prostaglandin G/H synthase-2 (i.e. COX-2) has been implicated 
in obesity in rodent models (13). In humans, COX-2 expression is higher in epicardial 
adipose tissue than subcutaneous, but lower than that of visceral adipose tissue (14). 
 While global gene expression analysis did not identify genes differentially regulated 
by dietary treatment, it did identify differences in mRNA abundance of genes related to 
excreted proteins, arachidonic acid metabolism, and chemokine signaling pathway between 
SQ and VIS adipose tissue.  These genes may be important with respect to obesity and 
adipose tissue inflammation and dysfunction.  Further investigation into these genes in VIS 
and SQ adipose tissue with a high fat dietary treatment is warranted. 
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 Tables 
 
Table 5. Metabolic profile of Ossabaw swine. 
Parameter Restricted Obese p value 
Insulin (pg/mL) 119.7±25.8 130.1±25.8 0.78 
Glucose (mg/dL 93.6±16.2 106.9±16.2 0.57 
HOMA-IR 0.57±0.15 0.75±0.15 0.42 
Cholesterol (mg/dL) 63.4±5.6 81.0±5.6 0.0463 
Triglycerides (mg/dL) 21.6±2.1 37.5±2.1 0.0005 
NEFA (mM) 0.28±0.06 0.43±0.06 0.13 
Endotoxin (ng/mL) 14.9±1.3 14.7±1.3 0.91 
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Table 6. Differentially expressed genes by depot (Q<0.01). 
Affy ID Rank
a
 GENE TITLE 
Q-
value 
Fold 
Change
b
 
Ssc.24864.1.A1_at 1 hypothetical LOC100515948 0.0007 13.40 
Ssc.8623.1.A1_at 4 Sec23 homolog A (S. cerevisiae) 0.0014 -5.08 
Ssc.5713.1.S1_at 7 gelatinase A 0.0015 -50.51 
Ssc.3450.1.S1_at 8 homeobox protein Hox-D8-like 0.0029 -4.87 
Ssc.12936.1.A1_at 10 keratocan-like 0.0033 -5.70 
Ssc.18608.1.S1_at 15 
cellular retinoic acid binding 
protein 1 
0.0039 1.60 
Ssc.15923.1.S1_at 18 fibroblast growth factor 7 0.0039 -0.25 
Ssc.25680.1.S1_at 19 mutS homolog 3 (E. coli) 0.0040 0.20 
Ssc.21925.1.S1_at 22 
complement C1q tumor necrosis 
factor-related protein 5-like 
0.0040 -3.53 
Ssc.2445.1.S1_at 23 
microfibrillar-associated protein 2-
like 
0.0040 -5.72 
Ssc.2464.1.S1_at 25 Stanniocalcin 1 0.0040 -4.30 
Ssc.21549.1.A1_at 28 
meningioma expressed antigen 5 
(hyaluronidase) 
0.0040 0.89 
Ssc.15266.1.S1_at 32 
15-hydroxyprostaglandin 
dehydrogenase [NAD+]-like 
0.0042 1.80 
Ssc.6327.1.S1_at 33 keratin, type I cytoskeletal 19-like 0.0042 5.95 
Ssc.21125.1.S1_at 35 oral-facial-digital syndrome 1 0.0045 -1.02 
Ssc.30175.1.A1_at 36 
carboxypeptidase X (M14 family), 
member 1 
0.0045 -8.90 
Ssc.16418.2.S1_at 37
c
 integrin beta-like protein 1-like 0.0052 -3.94 
Ssc.16589.1.S1_at 41 collagen, type VI, alpha 3 0.0053 -48.52 
Ssc.8573.1.A1_at 43 apolipoprotein D 0.0053 -40.40 
Ssc.30.1.S1_at 46 
proteasome (prosome, macropain) 
subunit, alpha type, 4 
0.0053 -7.89 
Ssc.19688.1.S1_at 47 
cholinergic receptor, nicotinic, 
alpha 1 (muscle) 
0.0053 -23.30 
Ssc.12795.1.S1_at 48 
three prime repair exonuclease 1-
like 
0.0055 -1.10 
Ssc.24330.1.S1_at 49 
cytochrome P450, family 7, 
subfamily B, polypeptide 1 
0.0056 2.89 
Ssc.4044.1.A1_at 52 hypothetical LOC100512560 0.0059 2.62 
Ssc.26893.1.A1_at 53 hemicentin-1-like 0.0059 2.64 
Ssc.26617.1.A1_at 54 
paired mesoderm homeobox 
protein 1-like 
0.0059 -5.25 
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Table 6. Differentially expressed genes by depot (Q<0.01) (continued). 
Ssc.5396.1.S1_at 59 Similar to transcription factor 21 0.0062 3.13 
Ssc.24864.2.S1_at 60 hypothetical LOC100515948 0.0062 2.08 
Ssc.9754.1.A1_at 62 
Ankyrin repeat and SOCS box-
containing 6 
0.0064 -0.44 
Ssc.24250.1.S1_at 63 
cellular retinoic acid binding 
protein 2 
0.0065 -11.22 
Ssc.18278.2.A1_at 66 nebulin-related anchoring protein 0.0067 -0.45 
Ssc.6058.1.S1_at 67 dual specificity phosphatase 1 0.0067 -34.67 
Ssc.6817.1.A1_a_at 73 tumor suppressor candidate 3-like 0.0068 1.93 
Ssc.2747.1.S1_at 74 homeobox protein Hox-B5-like 0.0068 1.74 
Ssc.1600.3.S1_at 78 
ribosomal protein S6 modification-
like protein B-like 
0.0068 1.21 
Ssc.226.1.S1_at 83 high-mobility group box 2 0.0068 1.61 
Ssc.26825.1.S1_at 85 zinc finger protein 330-like 0.0068 1.00 
Ssc.14851.1.S1_at 86 
amyloid beta (A4) precursor-like 
protein 2 
0.0068 0.87 
Ssc.11952.1.S1_at 87
c
 transmembrane protein 117-like 0.0068 -1.23 
Ssc.17345.1.S1_at 88 angiopoietin-like 4 0.0068 -2.56 
Ssc.19323.1.S1_at 89 protein NOXP20-like 0.0070 -6.46 
Ssc.24429.1.A1_at 90 sperm-specific antigen 2-like 0.0070 -0.20 
Ssc.1310.1.S1_at 91 prostaglandin E synthase 0.0070 -4.09 
Ssc.19136.1.S1_at 93 
latent-transforming growth factor 
beta-binding protein 2-like 
0.0071 1.73 
Ssc.11369.2.A1_at 97 
Der1-like domain family, member 
1 
0.0071 -2.80 
Ssc.8027.1.A1_at 98 
dickkopf homolog 3 (Xenopus 
laevis) 
0.0071 5.16 
Ssc.5895.1.A1_at 99 collagen, type VI, alpha 1 0.0071 -6.72 
Ssc.10793.1.A1_at 100 syndecan 2 0.0071 -10.35 
Ssc.20706.1.S1_at 102 
hypothetical protein 
LOC100523635 
0.0071 2.94 
Ssc.4048.1.A1_at 107 neogenin-like 0.0074 2.43 
Ssc.26172.1.S1_at 108 leprecan-like 4 0.0074 -1.01 
Ssc.4381.1.S1_at 111 septin 11 0.0077 -8.88 
Ssc.820.1.S1_at 113 alanyl (membrane) aminopeptidase 0.0079 -11.29 
Ssc.1986.1.S1_at 114 
Prostaglandin-endoperoxide 
synthase 1 
0.0079 2.31 
Ssc.2425.1.S1_at 115 zonula occludens 1 0.0079 5.21 
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Table 6. Differentially expressed genes by depot (Q<0.01) (continued). 
Ssc.11185.1.A1_at 117 
SH3 domain-containing kinase-
binding protein 1-like 
0.0079 -1.01 
Ssc.15233.1.S1_at 119 
Similar to Homeobox protein 
SIX1 (Sine oculis homeobox 
homolog 1) 
0.0079 -11.80 
Ssc.14134.1.S1_at 120 
polypeptide N-
acetylgalactosaminyltransferase 1-
like 
0.0079 -2.70 
Ssc.28359.1.A1_at 121 
hypothetical protein 
LOC100153390 
0.0079 -0.72 
Ssc.7769.2.S1_at 122 
lysophosphatidylglycerol 
acyltransferase 1 
0.0080 -7.40 
Ssc.1495.1.S1_a_at 125 
transcription elongation factor A 
protein 1-like 
0.0081 2.60 
Ssc.12446.1.A1_at 127 caspase-13-like 0.0081 -2.16 
Ssc.21869.1.S1_at 128 
src kinase-associated 
phosphoprotein 2-like 
0.0081 3.60 
Ssc.1091.2.S1_at 130 collagen, type I, alpha 1 0.0081 -5.53 
Ssc.5895.1.A2_at 132 Collagen, type VI, alpha 1 0.0081 -12.83 
Ssc.25217.1.S1_a_at 133 selenoprotein M 0.0081 -6.89 
Ssc.11628.1.A1_at 135 GPN-loop GTPase 1-like 0.0081 -1.14 
Ssc.15646.1.S1_at 136 lipase maturation factor 2-like 0.0081 -1.66 
Ssc.373.1.S1_at 137 matrix Gla protein 0.0081 35.16 
Ssc.8072.2.A1_at 139 
latent-transforming growth factor 
beta-binding protein 1-like 
0.0081 3.49 
Ssc.18454.1.A1_at 143 
transducin-like enhancer of split 1 
(E(sp1) homolog, Drosophila) 
0.0081 2.32 
Ssc.3919.1.S1_at 144 
cytosolic 5'-nucleotidase III-like 
protein-like 
0.0081 -3.73 
Ssc.19566.1.S1_at 147 secreted frizzled-related protein 4 0.0081 -28.97 
Ssc.27415.1.S1_at 148 
homeobox protein BarH-like 1-
like 
0.0082 2.65 
Ssc.12068.1.A1_at 149 Collagen, type VI, alpha 3 0.0082 -2.95 
Ssc.19119.1.A1_at 151 homeobox protein EMX2-like 0.0082 -1.00 
Ssc.5645.1.A1_at 152 
lamina-associated polypeptide 2, 
isoforms beta/gamma-like 
0.0084 1.58 
Ssc.3401.1.S1_at 153 
eukaryotic translation initiation 
factor 3, subunit M 
0.0084 2.94 
Ssc.11302.1.S2_at 155 
hypothetical protein 
LOC100152001 
0.0084 -67.71 
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Table 6. Differentially expressed genes by depot (Q<0.01) (continued). 
Ssc.4563.1.S1_a_at 158 
N-acetyltransferase 10 (GCN5-
related) 
0.0086 -0.34 
Ssc.6105.1.A1_at 161 plexin B1 0.0087 0.90 
Ssc.8000.1.A1_at 166 
O-linked N-acetylglucosamine 
(GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) 
0.0091 2.69 
Ssc.6736.1.S1_at 168 homeobox protein MSX-2-like 0.0094 -2.07 
Ssc.24393.1.S1_at 170 reticulocalbin-3-like 0.0095 -11.50 
Ssc.9061.1.A1_at 171 cystatin-M-like 0.0096 2.41 
Ssc.3832.1.S1_at 172 aquaporin 3 (Gill blood group) 0.0096 -40.64 
Ssc.17281.1.A1_at 174 
F-box and leucine-rich repeat 
protein 5 
0.0096 -6.54 
Ssc.25178.1.S1_a_at 175 
protein transport protein Sec24D-
like 
0.0096 -2.48 
Ssc.8564.1.A1_at 178 
Similar to very low density 
lipoprotein receptor VLDL-R2 
0.0096 7.06 
Ssc.22738.1.A1_at 179 protein MON2 homolog 0.0096 -1.49 
Ssc.2589.1.S1_at 180 troponin I type 3 (cardiac) 0.0096 2.36 
Ssc.4993.1.A1_at 181 
hypothetical protein 
LOC100517021 
0.0096 -19.82 
Ssc.272.1.S1_a_at 182 
CD55 molecule, decay 
accelerating factor for 
complement (Cromer blood 
group) 
0.0096 1.96 
Ssc.26447.1.S1_at 183 carboxypeptidase D 0.0099 1.09 
Ssc.18928.1.A1_at 185 
Mucosal vascular addressin cell 
adhesion molecule 1 
0.0099 1.37 
a
Ranking of all differentially expressed (Q<0.01) genes.   
b
Fold change in mRNA abundance for visceral adipose tissue relative to subcutaneous adipose tissue.  A 
positive fold change indicates increased mRNA abundance in visceral adipose tissue relative to subcutaneous 
adipose tissue and a negative fold change indicates decreased mRNA adundance. 
cResiduals of gene showed evidence of a non-normal distribution 
 
  
129 
 
Table 7. Gene ontology cellular component: extracellular region gene list
a
. 
Affy ID Gene Title Q-value Fold Change 
Ssc.12365.1.A1_at ADAM metallopeptidase with 
thrombospondin type 1 motif, 1 
0.0233 -6.48 
Ssc.11257.1.S1_at TIMP metallopeptidase inhibitor 2 0.0130 -34.61 
Ssc.6009.1.S1_at amylase, alpha 2B (pancreatic) 0.0440 -0.58 
Ssc.17345.1.S1_at angiopoietin-like 4 0.0068 -2.56 
Ssc.14474.1.S1_at Apomucin 0.0206 0.09 
Ssc.16624.1.S1_at 
carbonic anhydrase-related XI protein 
0.0342 0.58 
Ssc.1020.1.S1_at cathepsin K 0.0170 -28.91 
Ssc.657.1.A1_at chemokine (C-C motif) ligand 2 0.0327 -4.05 
Ssc.18613.1.S1_at chemokine (C-C motif) ligand 21 0.0180 1.94 
Ssc.4871.1.S1_at chemokine (C-X-C motif) ligand 2 0.0215 -2.08 
Ssc.31199.1.S1_at collagen, type V, alpha 1 0.0179 -0.80 
Ssc.61.1.S1_at complement component 3 0.0345 31.49 
Ssc.10245.2.A1_a_at Decorin 0.0281 -41.25 
Ssc.8027.1.A1_at dickkopf homolog 3 0.0071 5.16 
Ssc.16236.1.S1_at dipeptidyl-peptidase 4 0.0489 0.67 
Ssc.15923.1.S1_at fibroblast growth factor 7 
(keratinocyte growth factor) 
0.0039 -0.25 
Ssc.137.1.S1_at Ficolin 0.0184 -14.97 
Ssc.5833.1.A2_at follicle stimulating hormone, beta 
polypeptide 
0.0222 0.05 
Ssc.4747.1.S1_at Follistatin 0.0168 0.63 
Ssc.5713.1.S1_at gelatinase A 0.0015 -50.51 
Ssc.14246.1.S1_at Gelsolin 0.0302 -23.34 
Ssc.16231.1.S1_a_at insulin-like growth factor 1 0.0119 -2.68 
Ssc.15588.1.S2_at insulin-like growth factor binding 
protein 3 
0.0339 -16.60 
Ssc.15800.1.S1_at insulin-like growth factor binding 
protein 5 
0.0302 -10.14 
Ssc.14062.2.S1_a_at insulin-like growth factor binding 
protein 6 
0.0281 -20.02 
Ssc.62.2.S1_a_at interleukin 6 (interferon, beta 2) 0.0470 -0.47 
Ssc.373.1.S1_at matrix Gla protein 0.0081 35.16 
Ssc.734.1.S1_at matrix metallopeptidase 14 
(membrane-inserted) 
0.0418 -2.07 
Ssc.11194.1.S1_at plasminogen activator 0.0383 -2.24 
Ssc.196.1.S1_at plasminogen activator, tissue 0.0296 -6.52 
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Table 7. Gene ontology cellular component: extracellular region gene list
a
(Continued). 
Ssc.16228.1.S1_at platelet basic protein 0.0417 1.73 
Ssc.10510.1.A1_at Prolactin 0.0480 -0.12 
Ssc.14556.1.S1_at Proopiomelanocortin 0.0136 0.10 
Ssc.15695.1.S1_at retinol binding protein 4, plasma 0.0206 19.02 
Ssc.2464.1.S1_at stanniocalcin 1 0.0040 -4.30 
Ssc.5614.1.S1_at Tryptase 0.0413 0.49 
a
Gene list of over-represented family of genes (EASE Score=0.0050) that were differentially expressed 
(Q<0.05). 
b
Fold change in mRNA abundance for visceral adipose tissue relative to subcutaneous adipose tissue.  A 
positive fold change indicates increased mRNA abundance in visceral adipose tissue relative to 
subcutaneous adipose tissue and a negative fold change indicates decreased mRNA abundance. 
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Table 8. KEGG pathway: arachidonic acid metabolism gene list
a
. 
Affy ID Gene Title Q-value Fold Change 
Ssc.10974.1.S1_at arachidonate 12/15-lipoxygenase 0.0124 13.64 
Ssc.732.1.S1_at carbonyl reductase 2 0.0461 3.06 
Ssc.11267.1.S1_at cytochrome P450 2B22 0.0424 2.95 
Ssc.1310.1.S1_at microsomal prostaglandin E synthase-1 0.0070 -4.09 
Ssc.7314.1.A1_at prostaglandin G/H synthase-2 0.0195 -0.12 
Ssc.1986.1.S1_at prostaglandin-endoperoxide synthase 1 0.0079 2.31 
Ssc.8278.1.S1_at soluble epoxide hydrolase 0.0264 -4.27 
a
Gene list of over-represented family of genes (EASE Score=0.0152) that were differentially expressed 
(Q<0.05). 
b
Fold change in mRNA abundance for visceral adipose tissue relative to subcutaneous adipose tissue.  A 
positive fold change indicates increased mRNA abundance in visceral adipose tissue relative to subcutaneous 
adipose tissue and a negative fold change indicates decreased mRNA abundance. 
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Table 9. KEGG pathway: chemokine signaling pathway gene list
a
. 
Affy ID Gene Title Q-value Fold Change
b
 
Ssc.657.1.A1_at chemokine (C-C motif) ligand 2 0.0327 -4.04524 
Ssc.18613.1.S1_at chemokine (C-C motif) ligand 21 0.018 1.938086 
Ssc.19054.1.S1_a_at chemokine (C-C motif) receptor 3 0.0488 0.169559 
Ssc.4871.1.S1_at chemokine (C-X-C motif) ligand 2 0.0215 -2.07684 
Ssc.14176.1.A1_s_at glycogen synthase kinase 3 beta 0.015 -1.22895 
Ssc.16228.1.S1_at platelet basic protein 0.0417 1.727623 
Ssc.6025.1.S1_at 
signal transducer and activator of 
transcription 1 
0.0311 1.367214 
Ssc.10911.2.S1_at 
similar to Beta-adrenergic receptor 
kinase 2 (Beta-ARK-2) (G-protein-
coupled receptor kinase 3) 
0.0143 -3.14621 
Ssc.2140.1.S1_at 
similar to PTK2B protein tyrosine 
kinase 2 beta 
0.0471 0.422968 
Ssc.5093.1.A1_at 
similar to SHC-transforming protein 1 
(SH2 domain protein C1) (Src 
homology 2 domain-containing-
transforming protein C1) 
0.0407 -3.14165 
a
Gene list of over-represented family of genes (EASE Score=0.0152) that were differentially expressed 
(Q<0.05). 
b
Fold change in mRNA abundance for visceral adipose tissue relative to subcutaneous adipose tissue.  A 
positive fold change indicates increased mRNA abundance in visceral adipose tissue relative to subcutaneous 
adipose tissue and a negative fold change indicates decreased mRNA abundance. 
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CHAPTER 6. GENERAL CONCLUSIONS 
 The prevalence of obesity in the United States is continuing to rise (2-3) and places a 
significant burden on our health care system (11).  Research has identified that insulin 
resistance in obesity is related to adipose tissue inflammation (4) and that this is accompanied 
by macrophage infiltration into adipose tissue (12-13).  Rodent models have been pivotal to 
obesity and obesity-related research and the role of individual genes.  However, distinct 
differences between rodents and humans underscore the need for alternative comparative 
models.  Unlike humans, CRP is not an acute phase protein nor is it highly expressed in mice 
(10).  Additionally, mice macrophages are functionally different in that they produce NO via 
inducible nitric oxide synthase (8).  Swine are an attractive alternative model due to their 
comparative physiology and anatomy to humans.  In particular, Ossabaw swine are a suitable 
alternative as they can consistently develop multiple metabolic syndrome risk factors (9). 
 I first sought to characterize obesity-linked adipose tissue inflammation and 
macrophage phenotype in Ossabaw swine (Chapter 3).  Therefore, I feed Ossabaw swine for 
30 weeks with a restricted intake low-fat control diet, a high palm oil diet, or a high palm oil 
with n-3 fatty acids diet.  We determined that the major adipose tissue macrophage 
phenotype in Ossabaw swine is CD16
+
CD14
−
, which is likely anti-inflammatory.  High 
dietary palm oil did cause an increase in adipose tissue CD16
−
CD14
+
 macrophages, which a 
likely inflammatory, and this increase was attenuated by the addition of dietary n-3 fatty 
acids.  Concomitant with a largely anti-inflammatory adipose tissue macrophage phenotype, 
there was no induction of inflammation measured by serum CRP, TNF, IL-6, or IL-12.  
Serum adiponectin was decreased by the high palm oil diet, but this decrease was attenuated 
by the addition of n-3 fatty acids.  However, the increase in serum adiponectin by the 
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addition of n-3 fatty acids did not attenuate the decrease in longissimus dorsi AMPK 
phosphorylation.  Some individuals remain healthy despite obesity, and possess a favorable 
inflammation profile (5).  The ability to expand adipose tissue may afford protection against 
adipose tissue expansion.  As evidenced by Kim et al. (6), adipose tissue expansion 
attenuates inflammation due to obesity. 
 However, the metabolic profile of obese Ossabaw swine in this study was not entirely 
healthy.  There was no increase in serum cholesterol or triglycerides, but there was apparent 
hyperglycemia without hyperinsulinemia.  The lack of hyperinsulinemia suggests that there 
was impaired -cell function in the obese Ossabaw swine, which could be caused by a 
number of obesity related complications including ectopic lipid deposition in the pancreas.  
Although there was no ectopic lipid deposition in the liver or longissimus dorsi muscle.  
Challenging Ossabaw swine with insulin revealed that high dietary palm oil induced insulin 
resistance, but the addition of dietary n-3 fatty acids attenuated the palm oil-induced insulin 
resistance.  Despite the hyperglycemia and insulin resistance, the capacity to markedly 
expand adipose tissue may have afforded protection against obesity-linked inflammation.  
This demonstrates, at least in this study, that inflammation is not definitely linked to 
inflammation, at least in the parameters we measured. 
 Due to inflammation being largely absent, we hypothesized that the ability to expand 
adipose tissue protected Ossabaw swine against adipose tissue inflammation.  Therefore, we 
determined whether SVC-derived adipocytes from Ossabaw swine were protected from 
palmitate-induced inflammation and insulin resistance compared to Yorkshire SVC-derived 
adipocytes (Chapter 4).  We determined that NFB was equally activated in both Ossabaw 
and Yorkshire adipocytes in response to palmitate.  However, only Yorkshire adipocytes 
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secrete the chemokine IL-8 in response to palmitate treatment.  IL-8 is responsible for 
recruiting neutrophils to the site of injury and inflammation, and are present in adipose tissue 
after one week of high fat feeding in mice (1). The absence of palmitate-induced IL-8 
production by Ossabaw adipocytes may be involved in the lack of substantial adipose tissue 
inflammation seen in our first study.  Consistent with the lack of palmitate-induced IL-8 
production in adipocytes, there was no increase in serum or adipose tissue IL-8 in obese 
Ossabaw swine. 
 Palmitate decreased insulin-stimulated glucose uptake in both adipocyte genotypes.  
However, Ossabaw adipocytes had decreased basal and insulin-stimulated glucose uptake 
compared to Yorkshire adipocytes.  Although the fold increase for insulin-stimulated glucose 
uptake was equal between the two adipocyte genotypes.  Though there have been no direct 
comparisons, this in vitro data matches two separate in vivo insulin challenges in Ossabaw 
and Yorkshire swine, where Yorkshire swine comparably have more insulin sensitivity than 
Ossabaw swine.  Whether this decreases overall insulin sensitivity of Ossabaw swine 
contributes to the susceptibility of Ossabaw swine to develop insulin resistance remains to be 
determined. 
 Because of the potential for adipose expansion to protect against inflammation, we 
performed microarray analysis on subcutaneous and visceral adipose tissue of lean and obese 
Ossabaw swine (Chapter 5).  Therefore, Ossabaw swine were fed either a restricted or an ad 
libitum nutritionally adequate diet for 38 weeks.  Microarray analysis revealed no dietary 
treatment induced differences in gene expression after controlling for FDR.  Coinciding with 
this, there were no negative obesity-linked metabolic alterations.  The lack of a high fat diet 
is likely causative to the lack of metabolic alteration in obese Ossabaw swine.  The 
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importance of high fat in inducing metabolic alterations is evident in the fructose group of 
Lee et al. (7) which did not cause a negative metabolic profile.  There were 1494 differently 
expression genes by depot after controlling for FDR, of which 777 were annotated.  One 
gene ontology cellular component and two KEGG pathways were determined to contain 
over-represented genes from our significantly expressed genes by depot.  These were 
extracellular region, arachidonic acid metabolism, and chemokine signaling pathway, 
respectively.   
 Overall, we have demonstrated that Ossabaw swine have a favorable inflammatory 
profile in response to a high fat diet, despite morbid obesity.  Additionally, the inflammatory 
profile was not linked to negative metabolic consequences.  Potentially, the ability to expand 
adipose tissue protects against inflammation, which is supported by palmitate induced IL-8 
induction in Yorkshire, but not Ossabaw adipocytes.  This is further evidenced by the lack of 
obesity-linked microarray gene expression differences in Ossabaw swine when fed a diet 
without high fat.   
 This research can be furthered in multiple areas.  Perhaps most intriguing is whether 
the decreased basal and insulin-stimulated glucose uptake in Ossabaw adipocytes versus 
Yorkshire adipocytes is a component of the ability to Ossabaw swine to develop insulin 
resistance.  Additionally, genetic determination of the cause of the reduced glucose uptake 
and whether analogous conditions is a component of obesity-linked insulin resistance in 
humans.  Additionally, continued research into the capacity of Ossabaw swine to expand 
adipose tissue and its ability to afford protection against obesity-linked inflammation is an 
intriguing question, particularly if it is analogous to the metabolically healthy obese human 
population subset.  Finally, because of immunological differences between humans and mice, 
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further characterization of swine adipose tissue macrophages with regards to phenotype and 
function is an imminent research question to further the validation of the model for obesity 
and obesity-linked research.   
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